title,time_published,summary,ticker_sentiment
WHO Recommends Merck  ( MRK )  Oral Pill for Certain COVID Patients,20220304T132800,Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.,"[{'ticker': 'PFE', 'relevance_score': '0.154356', 'ticker_sentiment_score': '0.027726', 'ticker_sentiment_label': 'Neutral'}]"
"Merck  ( MRK )  Outperforms Industry, What's in Store for 2022?",20220307T125800,"Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.","[{'ticker': 'VRTX', 'relevance_score': '0.144853', 'ticker_sentiment_score': '0.247098', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AZN', 'relevance_score': '0.19231', 'ticker_sentiment_score': '0.004507', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GMDA', 'relevance_score': '0.144853', 'ticker_sentiment_score': '0.015473', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics to Present at Two Upcoming March Investor Conferences,20220307T210500,"HOUSTON, March  07, 2022   ( GLOBE NEWSWIRE )  -- Marker Therapeutics, Inc.  ( NASDAQ:MRKR ) , a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today a","[{'ticker': 'MRKR', 'relevance_score': '0.260838', 'ticker_sentiment_score': '0.011752', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics to Present at Two Upcoming March Investor Conferences,20220307T210500,"HOUSTON, March  07, 2022   ( GLOBE NEWSWIRE )  -- Marker Therapeutics, Inc.  ( NASDAQ:MRKR ) , a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today a","[{'ticker': 'MRKR', 'relevance_score': '0.321393', 'ticker_sentiment_score': '0.008377', 'ticker_sentiment_label': 'Neutral'}]"
Alpine  ( ALPN )  Down on FDA Partial Clinical Hold on Cancer Study,20220308T160600,The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.,"[{'ticker': 'CPRX', 'relevance_score': '0.21311', 'ticker_sentiment_score': '0.016072', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGTX', 'relevance_score': '0.21311', 'ticker_sentiment_score': '-0.031329', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ALPN', 'relevance_score': '0.411288', 'ticker_sentiment_score': '0.020062', 'ticker_sentiment_label': 'Neutral'}]"
US FDA approves AstraZeneca cancer drug Lynparza for treatment of breast cancer | The Financial Express,20220314T070419,The cancer drug Lynparza which has been jointly developed with US based Merck is used for patients who have already been treated with chemotherapy either before or after surgery.,"[{'ticker': 'AZN', 'relevance_score': '0.543004', 'ticker_sentiment_score': '0.039844', 'ticker_sentiment_label': 'Neutral'}]"
Merck's Covid-19 Pill Heavily Used So Far Despite Concerns,20220314T093000,"Doctors have turned to the drug, called molnupiravir, partly because a rival Pfizer pill has been in limited supply.","[{'ticker': 'PFE', 'relevance_score': '0.453099', 'ticker_sentiment_score': '0.296263', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer,20220314T103255,"The FDA has approved AstraZeneca Plc's  ( NASDAQ: AZN )  cancer drug, jointly developed with Merck & Co Inc  ( NYSE: MRK )  to treat patients with early-stage breast cancer with certain mutations.
The agency approved Lynparza  ( olaparib )  for patients with a form of genetically mutated high-risk e","[{'ticker': 'AZN', 'relevance_score': '0.539214', 'ticker_sentiment_score': '0.004066', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MYGN', 'relevance_score': '0.287706', 'ticker_sentiment_score': '0.014804', 'ticker_sentiment_label': 'Neutral'}]"
"AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use",20220314T143400,FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.,"[{'ticker': 'AZN', 'relevance_score': '0.336738', 'ticker_sentiment_score': '0.014402', 'ticker_sentiment_label': 'Neutral'}]"
Merck's COVID-19 pill heavily used so far despite concerns,20220315T112115,"A new COVID-19 pill from Merck & Co. and Ridgeback Biotherapeutics LP has been more widely used than expected since rolling out late last year, though regulators and many doctors consider it a last resort.","[{'ticker': 'OSH', 'relevance_score': '0.039542', 'ticker_sentiment_score': '0.061656', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.195783', 'ticker_sentiment_score': '0.105255', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IQV', 'relevance_score': '0.039542', 'ticker_sentiment_score': '0.015743', 'ticker_sentiment_label': 'Neutral'}]"
Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients,20220315T132655,"Merck & Co Inc  ( NYSE: MRK )  will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer  ( mCRPC ) .
The trial included mCRPC patients who progressed after treatment with chemotherapy and either abiraterone acetate or e","[{'ticker': 'AZN', 'relevance_score': '0.191473', 'ticker_sentiment_score': '0.000534', 'ticker_sentiment_label': 'Neutral'}]"
Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® in Combination with LYNPARZA® in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility,20220315T113920,"Merck  (  NYSE: MRK  )  , known as MSD outside the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-010 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic castration-resistant prostate cancer  (  mCRPC  )  who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. Merck is discontinuing the study following the recommendation of an independent Data Monitoring Committee  (  DMC  )  after the DMC reviewed data from a planned interim analysis. At the interim analysis, the combination of KEYTRUDA and LYNPARZA did not demonstrate a benefit in overall survival  (  OS  )  , one of the study's dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide. The trial's other dual primary endpoint, radiographic progression free survival  (  rPFS  )  , was evaluated at an earlier interim analysis and did not demonstrate improvement compared to the control arm. The safety profile of KEYTRUDA in combination with LYNPARZA in this trial was consistent with that observed in previously reported studies for the individual therapies; however, the combination was associated with a higher incidence of grade 3-5 adverse events and drug-related serious adverse events, compared to the control arm. Merck will inform study investigators of the recommendation from the DMC and advise patients in the study to speak to their physician regarding treatment. Data from this study will be presented at an upcoming scientific congress.","[{'ticker': 'CURN', 'relevance_score': '0.003747', 'ticker_sentiment_score': '-0.026492', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'STQN', 'relevance_score': '0.003747', 'ticker_sentiment_score': '0.260241', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NHPEF', 'relevance_score': '0.003747', 'ticker_sentiment_score': '0.260241', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'FB', 'relevance_score': '0.003747', 'ticker_sentiment_score': '0.514156', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'AZN', 'relevance_score': '0.01124', 'ticker_sentiment_score': '0.020991', 'ticker_sentiment_label': 'Neutral'}]"
"The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial",20220315T114619,"Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne
Anaptys Bio, Inc.  ( NASDAQ: ANAB )  said the Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne did not demonst","[{'ticker': 'SYRS', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.000797', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IDYA', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.003973', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GMDA', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.000414', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ATNX', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.000104', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BBI', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.000962', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ALT', 'relevance_score': '0.073434', 'ticker_sentiment_score': '-0.000243', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BTTX', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.251631', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'TCON', 'relevance_score': '0.073434', 'ticker_sentiment_score': '-0.003169', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ANIP', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.00077', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ANAB', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.099787', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IMRA', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.001405', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DTIL', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.002139', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SXTC', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.000763', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.109956', 'ticker_sentiment_score': '-0.020775', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CGTX', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.0027', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EXEL', 'relevance_score': '0.109956', 'ticker_sentiment_score': '-0.067745', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ATHX', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.007218', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.003456', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BIIB', 'relevance_score': '0.073434', 'ticker_sentiment_score': '0.003456', 'ticker_sentiment_label': 'Neutral'}]"
"Fosun sees profit rise, set to make generic Pfizer, Merck Covid-19 pills",20220324T102057,"Fosun International, one of China's largest private conglomerates, has stepped up preparations to produce cheaper generic versions of Covid-19 medications developed by American pharmaceutical giants Pfizer and Merck.Its subsidiary Shanghai Fosun Pharmaceutical Group is looking into which of its exis","[{'ticker': 'SZIHF', 'relevance_score': '0.066784', 'ticker_sentiment_score': '-0.040133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FOSUF', 'relevance_score': '0.685386', 'ticker_sentiment_score': '-0.004471', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SFOSF', 'relevance_score': '0.066784', 'ticker_sentiment_score': '0.008972', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.198493', 'ticker_sentiment_score': '0.00193', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BNTX', 'relevance_score': '0.066784', 'ticker_sentiment_score': '-0.040133', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds",20220324T141400,FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma.  Pfizer's (PFE) late-stage ulcerative colitis study on etrasimod meets goal.,"[{'ticker': 'PFE', 'relevance_score': '0.284266', 'ticker_sentiment_score': '0.006276', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.058061', 'ticker_sentiment_score': '0.100203', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer",20220325T103500,"Novartis, Merck and Pfizer have been included in this Analyst Blog.","[{'ticker': 'PFE', 'relevance_score': '0.242608', 'ticker_sentiment_score': '-0.046488', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.041061', 'ticker_sentiment_score': '0.100203', 'ticker_sentiment_label': 'Neutral'}]"
"The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study",20220401T130828,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Reata Completes Regulatory Filing For Omaveloxolone As Treatment Option For Neurodegenerative Movement Disorder
Reata Pharmaceuticals, Inc.  ( NASDAQ: RETA )  said it has completed filing the rolling su","[{'ticker': 'IMMP', 'relevance_score': '0.1081', 'ticker_sentiment_score': '0.015145', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RETA', 'relevance_score': '0.1081', 'ticker_sentiment_score': '0.022097', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TTOO', 'relevance_score': '0.16153', 'ticker_sentiment_score': '0.007544', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABIO', 'relevance_score': '0.1081', 'ticker_sentiment_score': '0.009089', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SLS', 'relevance_score': '0.1081', 'ticker_sentiment_score': '0.005988', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SPRO', 'relevance_score': '0.1081', 'ticker_sentiment_score': '-0.156425', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'ESALF', 'relevance_score': '0.16153', 'ticker_sentiment_score': '0.019246', 'ticker_sentiment_label': 'Neutral'}]"
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® Supplemental Biologics License Application,20220325T113659,"Bristol Myers Squibb  (  NYSE: BMY  )  today announced that the U.S. Food and Drug Administration  (  FDA  )  has extended the review of the supplemental biologics license application  (  sBLA  )  for Reblozyl ®  (  luspatercept-aamt  )  for the treatment of anemia in adults with non-transfusion-dependent  (  NTD  )  beta thalassemia to June 27, 2022. Reblozyl is being developed and commercialized through a global collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, following Merck's acquisition of Acceleron Pharma, Inc. in November 2021.","[{'ticker': 'FB', 'relevance_score': '0.039732', 'ticker_sentiment_score': '0.090641', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.514474', 'ticker_sentiment_score': '0.185056', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck's  ( MRK )  Pneumococcal Vaccine sBLA Faces FDA Delay,20220404T144000,"Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.","[{'ticker': 'SLDB', 'relevance_score': '0.422755', 'ticker_sentiment_score': '-0.146348', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BLU', 'relevance_score': '0.176438', 'ticker_sentiment_score': '0.048821', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.176438', 'ticker_sentiment_score': '0.014823', 'ticker_sentiment_label': 'Neutral'}]"
Merck Surges After Naming Its Next Blockbuster Biz: Heart Disease,20220405T162400,Merck Stock Surges; Will This New Segment Hit $10 Billion Projection? Investor's Business Daily,"[{'ticker': 'BABA', 'relevance_score': '0.091965', 'ticker_sentiment_score': '-0.122285', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BGNE', 'relevance_score': '0.091965', 'ticker_sentiment_score': '-0.122285', 'ticker_sentiment_label': 'Neutral'}]"
Will Merck  ( MRK )  Beat Expectations This Earnings Season?,20220426T133100,"Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.","[{'ticker': 'AZN', 'relevance_score': '0.199488', 'ticker_sentiment_score': '0.084745', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.247888', 'ticker_sentiment_score': '0.055814', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.247888', 'ticker_sentiment_score': '0.016751', 'ticker_sentiment_label': 'Neutral'}]"
5 Blue-Chip Stocks Likely to Gain on Earnings Results This Week,20220425T101800,"Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.","[{'ticker': 'CVX', 'relevance_score': '0.221078', 'ticker_sentiment_score': '0.23749', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'KO', 'relevance_score': '0.291818', 'ticker_sentiment_score': '0.252188', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AMGN', 'relevance_score': '0.221078', 'ticker_sentiment_score': '0.195096', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'V', 'relevance_score': '0.256719', 'ticker_sentiment_score': '0.191373', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"The Zacks Analyst Blog Highlights Amgen, Chevron, Coca-Cola, Visa and Merck",20220426T095000,"Amgen, Chevron, Coca-Cola, Visa and Merck have been included in this Analyst Blog.","[{'ticker': 'CVX', 'relevance_score': '0.204738', 'ticker_sentiment_score': '0.184532', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'KO', 'relevance_score': '0.261335', 'ticker_sentiment_score': '0.171951', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AMGN', 'relevance_score': '0.204738', 'ticker_sentiment_score': '0.141072', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'V', 'relevance_score': '0.233192', 'ticker_sentiment_score': '0.139565', 'ticker_sentiment_label': 'Neutral'}]"
"Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer",20220516T162435,Athenex Inc ( NASDAQ: ATNX ) announced a clinical trial collaboration and supply agreement with Merck Co & Inc ( NYSE: MRK ) . The agreement applies to the expansion phase of the Phase 1 clinical trial ...Full story available on Benzinga.com,"[{'ticker': 'ATNX', 'relevance_score': '0.667868', 'ticker_sentiment_score': '0.001563', 'ticker_sentiment_label': 'Neutral'}]"
New Analysts Initiate Coverage: Top 5 Stocks on Radar,20220513T110100,"Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Bancolombia (CIB), Lantheus (LNTH), A-Mark (AMRK), Patrick (PATK) and LCI (LCII).","[{'ticker': 'AMRK', 'relevance_score': '0.153519', 'ticker_sentiment_score': '0.007414', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LCII', 'relevance_score': '0.153519', 'ticker_sentiment_score': '0.007414', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CIB', 'relevance_score': '0.153519', 'ticker_sentiment_score': '0.007414', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LNTH', 'relevance_score': '0.19123', 'ticker_sentiment_score': '0.007414', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PATK', 'relevance_score': '0.153519', 'ticker_sentiment_score': '0.007414', 'ticker_sentiment_label': 'Neutral'}]"
"Tesla, Occidental rise; New Relic, Merck fall",20220513T202741,"NEW YORK ( AP ) - Stocks that traded heavily or had substantial price changes Friday: Motorola Solutions Inc., up $13.75 to $215.29. Natural Alternatives International Inc., up $1.47 to $10.48. Investors were encouraged by the nutritional supplement maker's financial results and forecast.","[{'ticker': 'RSTGF', 'relevance_score': '0.353562', 'ticker_sentiment_score': '0.006031', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MSI', 'relevance_score': '0.353562', 'ticker_sentiment_score': '0.001372', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JOBY', 'relevance_score': '0.353562', 'ticker_sentiment_score': '0.00854', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FRGI', 'relevance_score': '0.353562', 'ticker_sentiment_score': '0.006031', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NAII', 'relevance_score': '0.353562', 'ticker_sentiment_score': '0.006619', 'ticker_sentiment_label': 'Neutral'}]"
Merck's  ( MRK )  Keytruda Gets CHMP Nod for Expanded Melanoma Use,20220523T141400,"Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.","[{'ticker': 'ALKS', 'relevance_score': '0.250232', 'ticker_sentiment_score': '-0.064582', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SESN', 'relevance_score': '0.201398', 'ticker_sentiment_score': '-0.104866', 'ticker_sentiment_label': 'Neutral'}]"
"Covid-19 Vaccine and Drug Sales, Once Booming, Plateau",20220524T093300,"Merck, J&J and some other drugmakers are dialing back sales estimates now that supplies are ample and many people are vaccinated.","[{'ticker': 'JNJ', 'relevance_score': '0.690822', 'ticker_sentiment_score': '0.061327', 'ticker_sentiment_label': 'Neutral'}]"
Regeneron Dives On $1.1 Billion Deal To Deepen Its Merck Cancer Rivalry,20220602T170100,Regeneron Stock Tumbles As Investors Doubt $1.1 Billion Cancer Deal Investor's Business Daily,"[{'ticker': 'REGN', 'relevance_score': '0.153275', 'ticker_sentiment_score': '-0.0181', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VEEV', 'relevance_score': '0.076995', 'ticker_sentiment_score': '-0.576489', 'ticker_sentiment_label': 'Bearish'}, {'ticker': 'SNY', 'relevance_score': '0.560594', 'ticker_sentiment_score': '-0.038879', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA,20220614T143300,"The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.","[{'ticker': 'ALKS', 'relevance_score': '0.349329', 'ticker_sentiment_score': '-0.039659', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BLU', 'relevance_score': '0.294093', 'ticker_sentiment_score': '-0.073743', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SESN', 'relevance_score': '0.294093', 'ticker_sentiment_score': '-0.075168', 'ticker_sentiment_label': 'Neutral'}]"
Is There A Better Pick Over Merck Stock In Animal Health Space?,20220614T140029,"There is more to the comparison, and in the sections below, we discuss why we believe that ZTS stock will offer better returns than MRK stock in the next three years.","[{'ticker': 'EA', 'relevance_score': '0.044551', 'ticker_sentiment_score': '-0.163859', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'ZTS', 'relevance_score': '0.837481', 'ticker_sentiment_score': '0.118', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EBS', 'relevance_score': '0.044551', 'ticker_sentiment_score': '-0.163859', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Merck Acquisition Would Test Emboldened Regulators,20220622T160100,A possible tie-up between Merck and Seagen makes strategic sense but will be closely scrutinized by antitrust officials seeking to toughen their approach to pharma mergers.,"[{'ticker': 'SGEN', 'relevance_score': '0.364453', 'ticker_sentiment_score': '-0.177463', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Merck's  ( MRK )  Pneumococcal Vaccine Gets FDA Nod for Kids,20220623T123900,"Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.","[{'ticker': 'ALKS', 'relevance_score': '0.367774', 'ticker_sentiment_score': '-0.021155', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.12675', 'ticker_sentiment_score': '0.004161', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SESN', 'relevance_score': '0.309982', 'ticker_sentiment_score': '-0.037536', 'ticker_sentiment_label': 'Neutral'}]"
Merck Clocks Wins Against Pfizer in Pneumococcal Vaccine Market,20220623T134600,Merck Gains Against Pfizer in Pneumococcal Vaccine Market ...,"[{'ticker': 'PFE', 'relevance_score': '0.423606', 'ticker_sentiment_score': '0.030066', 'ticker_sentiment_label': 'Neutral'}]"
News Exclusive | Merck Pushes Forward With Potential Deal for Seagen,20220623T233800,The talks have picked up pace and the two companies are scheduled to meet this week.,"[{'ticker': 'SGEN', 'relevance_score': '0.779232', 'ticker_sentiment_score': '0.01856', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J",20220701T105700,"Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.","[{'ticker': 'MRNA', 'relevance_score': '0.080377', 'ticker_sentiment_score': '0.033342', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.276045', 'ticker_sentiment_score': '0.041295', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BNTX', 'relevance_score': '0.080377', 'ticker_sentiment_score': '0.033342', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.12031', 'ticker_sentiment_score': '0.015567', 'ticker_sentiment_label': 'Neutral'}]"
Merck Covid-19 Pill Prescribed Frequently in Some Countries Despite Low Efficacy,20220703T110300,"Doctors in some countries, such as Australia and Japan, are prescribing Merck's Covid-19 antiviral pill more frequently than Pfizer's Paxlovid, citing a risk of drug interactions.","[{'ticker': 'PFE', 'relevance_score': '0.469744', 'ticker_sentiment_score': '-0.008889', 'ticker_sentiment_label': 'Neutral'}]"
A $41.8 Billion Global Opportunity for Small Molecule Drug Discovery by 2026 - New Research from StrategyR,20220704T104500,"• Access to our digital archives and MarketGlass Research Platform Companies: 21 - Players covered include AstraZeneca PLC. Boehringer Ingelheim International GmbH. Bristol-Myers Squibb Company. Gilead Sciences, Inc. GlaxoSmithKline PLC. Johnson & Johnson. Merck & Co., Inc. Pfizer, Inc.","[{'ticker': 'GILD', 'relevance_score': '0.053569', 'ticker_sentiment_score': '0.000476', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TEVA', 'relevance_score': '0.106897', 'ticker_sentiment_score': '0.000476', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.053569', 'ticker_sentiment_score': '0.000476', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.159745', 'ticker_sentiment_score': '0.000476', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.053569', 'ticker_sentiment_score': '0.000476', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.106897', 'ticker_sentiment_score': '0.000476', 'ticker_sentiment_label': 'Neutral'}]"
News Exclusive | Merck Is in Advanced Talks to Buy Seagen,20220707T024400,Deal could be worth roughly $40 billion or more.,"[{'ticker': 'SGEN', 'relevance_score': '0.790605', 'ticker_sentiment_score': '0.010821', 'ticker_sentiment_label': 'Neutral'}]"
Merck in advanced talks to buy Seagen in $40-billion deal - WSJ,20220707T025100,Merck in advanced talks to buy Seagen in $40-billion deal ...,"[{'ticker': 'SGEN', 'relevance_score': '0.828782', 'ticker_sentiment_score': '-0.13825', 'ticker_sentiment_label': 'Neutral'}]"
Merck in talks to buy cancer biotech Seagen for about $40 billion,20220707T025800,"Merck & Co. is in advanced talks to acquire Seagen Inc. and is aiming to finalize a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more.","[{'ticker': 'SGEN', 'relevance_score': '0.921804', 'ticker_sentiment_score': '0.011353', 'ticker_sentiment_label': 'Neutral'}]"
Merck in talks to buy cancer biotech Seagen: report,20220707T042150,"Drugmaker Merck & Co is reportedly in advanced talks to buy cancer-focused biotech company Seagen Inc. The deal could be worth roughly $40 billion or more, according to the Wall Street Journal. A deal would help Merck add to its cancer drug portfolio.","[{'ticker': 'SGEN', 'relevance_score': '0.823027', 'ticker_sentiment_score': '-0.077525', 'ticker_sentiment_label': 'Neutral'}]"
"Should You Buy, Sell, Or Hold Roche Stock At $42?",20220705T100008,"This marks an underperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 22%, Pfizer stock rising 41%, Merck stock up 5%, and the S&P 500 index rising 17% over the same period.","[{'ticker': 'IDXX', 'relevance_score': '0.048959', 'ticker_sentiment_score': '0.266748', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ENTG', 'relevance_score': '0.048959', 'ticker_sentiment_score': '0.266748', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PFE', 'relevance_score': '0.048959', 'ticker_sentiment_score': '0.023383', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.048959', 'ticker_sentiment_score': '0.023383', 'ticker_sentiment_label': 'Neutral'}]"
3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health,20220713T133100,"Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.","[{'ticker': 'ELAN', 'relevance_score': '0.045569', 'ticker_sentiment_score': '0.25323', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'JAZZ', 'relevance_score': '0.090989', 'ticker_sentiment_score': '0.206545', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Roche, Merck & Co, and Bayer Among Leading Companies in the Glioblastoma Multiforme Market | GlobalData Plc",20220714T111500,The US is expected to retain its position as the largest market for glioblastoma multiforme in 2030 The US is expected to retain its position as the largest market for glioblastoma multiforme in ...,"[{'ticker': 'III', 'relevance_score': '0.168255', 'ticker_sentiment_score': '0.137123', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KZIA', 'relevance_score': '0.033894', 'ticker_sentiment_score': '0.099679', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KTRA', 'relevance_score': '0.033894', 'ticker_sentiment_score': '0.099679', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals",20220713T113700,"Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals are part of Zacks top Analyst Blog.","[{'ticker': 'ENB', 'relevance_score': '0.2035', 'ticker_sentiment_score': '0.209589', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'TM', 'relevance_score': '0.269033', 'ticker_sentiment_score': '0.133533', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FUJHF', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.107357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KO', 'relevance_score': '0.2035', 'ticker_sentiment_score': '0.280364', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'REGN', 'relevance_score': '0.2035', 'ticker_sentiment_score': '0.209589', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Top Stock Reports for Coca-Cola, Merck & Toyota Motor",20220712T200500,"Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Merck & Co., Inc. (MRK) and Toyota Motor Corp. (TM).","[{'ticker': 'ENB', 'relevance_score': '0.128478', 'ticker_sentiment_score': '0.120294', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TM', 'relevance_score': '0.253646', 'ticker_sentiment_score': '0.031', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FUJHF', 'relevance_score': '0.064449', 'ticker_sentiment_score': '0.103099', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KO', 'relevance_score': '0.191675', 'ticker_sentiment_score': '0.193065', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'REGN', 'relevance_score': '0.128478', 'ticker_sentiment_score': '0.120294', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HSBC', 'relevance_score': '0.128478', 'ticker_sentiment_score': '0.120294', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie",20220725T102100,"J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.","[{'ticker': 'ABBV', 'relevance_score': '0.335709', 'ticker_sentiment_score': '0.236027', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'LDNXF', 'relevance_score': '0.043264', 'ticker_sentiment_score': '0.051658', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GLAXD', 'relevance_score': '0.0864', 'ticker_sentiment_score': '0.070804', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.043264', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.043264', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.0864', 'ticker_sentiment_score': '-0.027255', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FOREX:USD', 'relevance_score': '0.043264', 'ticker_sentiment_score': '0.192101', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
MRK: 2 Stocks Hedge Funds Have Been Buying up in 2022,20220725T124349,MRK: 2 Stocks Hedge Funds Have Been Buying up in ...,"[{'ticker': 'PFE', 'relevance_score': '0.348452', 'ticker_sentiment_score': '0.196755', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck  ( MRK )  to Report Q2 Earnings: What's in the Cards?,20220725T150600,"Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.","[{'ticker': 'AZN', 'relevance_score': '0.390396', 'ticker_sentiment_score': '0.113799', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BNTX', 'relevance_score': '0.201523', 'ticker_sentiment_score': '0.056828', 'ticker_sentiment_label': 'Neutral'}]"
"Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie",20220722T094900,"Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.","[{'ticker': 'SRTS', 'relevance_score': '0.265089', 'ticker_sentiment_score': '-0.00613', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.315493', 'ticker_sentiment_score': '0.129542', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRVI', 'relevance_score': '0.213517', 'ticker_sentiment_score': '0.087461', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PETQ', 'relevance_score': '0.213517', 'ticker_sentiment_score': '0.017256', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca",20220801T121000,"GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.","[{'ticker': 'AZN', 'relevance_score': '0.308062', 'ticker_sentiment_score': '0.22942', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NVO', 'relevance_score': '0.045139', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.265859', 'ticker_sentiment_score': '0.296358', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SNY', 'relevance_score': '0.265859', 'ticker_sentiment_score': '0.298284', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment,20220801T151819,"Immutep Limited IMMP announced new interim data from 2nd line non-small cell lung cancer ( NSCLC ) patients ( Part B ) in the Phase 2 TACTI-002 trial. Part B evaluates Immutep's lead product candidate, eftilagimod alpha ( efti or IMP321 ) , in combination with Merck & Co Inc's MRK ...","[{'ticker': 'IMMP', 'relevance_score': '0.528475', 'ticker_sentiment_score': '-0.402144', 'ticker_sentiment_label': 'Bearish'}]"
ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off,20220811T145212,ALX Oncology Holdings ALXO has initiated a Phase 2 investigator-sponsored study of evorpacept in combination with Eli Lilly's LLY ERBITUX ( cetuximab ) and Merck's MRK KEYTRUDA ( pembrolizumab ) in patients with refractory microsatellite stable metastatic colorectal cancer ( mCRC ) .,"[{'ticker': 'ALXO', 'relevance_score': '0.304114', 'ticker_sentiment_score': '0.0647', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LLY', 'relevance_score': '0.154951', 'ticker_sentiment_score': '0.010759', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics Reports Q2 2022 Operating and Financial Results,20220811T202200,"HOUSTON, Aug. 11, 2022 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today ...","[{'ticker': 'MRKR', 'relevance_score': '0.100029', 'ticker_sentiment_score': '-0.042699', 'ticker_sentiment_label': 'Neutral'}]"
Merck Gets FDA Fast Track Status For Chronic Kidney Disease Candidate,20220823T112925,The U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for Merck's MRK lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease ( ESRD ) .,"[{'ticker': 'KNBWY', 'relevance_score': '0.034933', 'ticker_sentiment_score': '0.071146', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KYKOF', 'relevance_score': '0.034933', 'ticker_sentiment_score': '0.071146', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNGX', 'relevance_score': '0.173333', 'ticker_sentiment_score': '0.144906', 'ticker_sentiment_label': 'Neutral'}]"
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,20220823T225342,The U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for Merck's MRK lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease ( ESRD ) .,"[{'ticker': 'NFLX', 'relevance_score': '0.107255', 'ticker_sentiment_score': '-0.002283', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BGNE', 'relevance_score': '0.080548', 'ticker_sentiment_score': '0.096668', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KALV', 'relevance_score': '0.053749', 'ticker_sentiment_score': '0.022994', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SWI', 'relevance_score': '0.080548', 'ticker_sentiment_score': '-0.013481', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BKYI', 'relevance_score': '0.160277', 'ticker_sentiment_score': '0.134356', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TWTR', 'relevance_score': '0.053749', 'ticker_sentiment_score': '0.367999', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'ARQT', 'relevance_score': '0.053749', 'ticker_sentiment_score': '0.073746', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JAGX', 'relevance_score': '0.080548', 'ticker_sentiment_score': '-0.013421', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MMM', 'relevance_score': '0.053749', 'ticker_sentiment_score': '0.166001', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AMGN', 'relevance_score': '0.080548', 'ticker_sentiment_score': '0.148817', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MSFT', 'relevance_score': '0.080548', 'ticker_sentiment_score': '0.014543', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SRNE', 'relevance_score': '0.053749', 'ticker_sentiment_score': '0.13173', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GDDY', 'relevance_score': '0.053749', 'ticker_sentiment_score': '0.143739', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CZR', 'relevance_score': '0.02689', 'ticker_sentiment_score': '0.069298', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SYBX', 'relevance_score': '0.080548', 'ticker_sentiment_score': '0.14472', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SAFRF', 'relevance_score': '0.02689', 'ticker_sentiment_score': '0.157695', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'FJTSF', 'relevance_score': '0.02689', 'ticker_sentiment_score': '0.157695', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Novartis Ag  ( NVS )  - Novartis Appoints Merck Executive As Research Head,20220901T114333,"Novartis AG NVS has appointed Merck executive Fiona Marshall as president of the Novartis Institutes for Biomedical Research to replace Jay Bradner, who is stepping down after seven years as research head.","[{'ticker': 'SOLTF', 'relevance_score': '0.229149', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GSK', 'relevance_score': '0.439786', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVS', 'relevance_score': '0.617765', 'ticker_sentiment_score': '0.153483', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Is Humira Maker A Better Bet Over Merck Stock?,20220901T130000,"There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer better returns than MRK stock in the next three years.","[{'ticker': 'XYL', 'relevance_score': '0.04111', 'ticker_sentiment_score': '0.137819', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.743214', 'ticker_sentiment_score': '0.440322', 'ticker_sentiment_label': 'Bullish'}]"
MRK: 5 Dividend Stocks to Buy and Hold Forever,20220901T212035,"Record high inflation, monetary policy tightening to control it, and the consequent fears of an economic slowdown have induced pessimism among investors and led to significant price declines for several stocks from their highs.","[{'ticker': 'WW', 'relevance_score': '0.037242', 'ticker_sentiment_score': '0.183637', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ABT', 'relevance_score': '0.148159', 'ticker_sentiment_score': '0.153856', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AZN', 'relevance_score': '0.037242', 'ticker_sentiment_score': '-0.076091', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CI', 'relevance_score': '0.184598', 'ticker_sentiment_score': '0.167083', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'OSCR', 'relevance_score': '0.037242', 'ticker_sentiment_score': '0.142132', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'USAC', 'relevance_score': '0.037242', 'ticker_sentiment_score': '-0.034952', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KRO', 'relevance_score': '0.166423', 'ticker_sentiment_score': '0.086424', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SUN', 'relevance_score': '0.018626', 'ticker_sentiment_score': '-0.031824', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CB', 'relevance_score': '0.037242', 'ticker_sentiment_score': '-0.007732', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ET', 'relevance_score': '0.291254', 'ticker_sentiment_score': '0.275657', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
USD 461.88 million growth in Silicone Gel Market - Global Market Analysis and Forecast Model,20220910T003000,"CRI SIL Silicone Technologies LLC, DuPont de Nemours Inc., Elkem ASA, Evonik Industries AG, Fuji Silysia Chemical Ltd., Henkel AG and Co. KGaA, KCC Co. Ltd., Merck KGaA, Momentive Performance Materials Inc., Nissan Chemical Corp., North Coast Medical Inc., Novagard Solutions Inc., Shin Etsu ...","[{'ticker': 'DD', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SHECF', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EVKIF', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'WKCMF', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MTLHF', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HENKY', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MSBHF', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NNCHY', 'relevance_score': '0.050894', 'ticker_sentiment_score': '0.02774', 'ticker_sentiment_label': 'Neutral'}]"
How Merck's Early Gamble With Keytruda Is Still Paying Off In 2022,20220911T081500,Merck Stock: How A Gamble In 2011 Is Still Paying Off In 2022 | Investor's Business Daily Investor's Business Daily ...,"[{'ticker': 'SGEN', 'relevance_score': '0.124809', 'ticker_sentiment_score': '-0.023633', 'ticker_sentiment_label': 'Neutral'}]"
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA®  ( pembrolizumab )  in ABILITY Trial,20220913T110000,"ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck's KEYTRUDA® ( pembrolizumab ) for treatment of patients with advanced solid tumors ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with ...","[{'ticker': 'MDNA', 'relevance_score': '0.191675', 'ticker_sentiment_score': '0.095838', 'ticker_sentiment_label': 'Neutral'}]"
"Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® with KEYTRUDA® and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer - Investing News Network",20220912T132212,"Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® with KEYTRUDA® and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer Investing News Network ...","[{'ticker': 'ALPMF', 'relevance_score': '0.012225', 'ticker_sentiment_score': '-0.028301', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CURN', 'relevance_score': '0.00815', 'ticker_sentiment_score': '0.05755', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.004075', 'ticker_sentiment_score': '0.190901', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.004075', 'ticker_sentiment_score': '0.190901', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NHPEF', 'relevance_score': '0.004075', 'ticker_sentiment_score': '0.039011', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.052936', 'ticker_sentiment_score': '-0.021001', 'ticker_sentiment_label': 'Neutral'}]"
"Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® with KEYTRUDA® and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer - Investing News Network",20220912T132212,"Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® with KEYTRUDA® and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer Investing News Network ...","[{'ticker': 'ALPMF', 'relevance_score': '0.016741', 'ticker_sentiment_score': '-0.030187', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CURN', 'relevance_score': '0.008371', 'ticker_sentiment_score': '0.062776', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.004185', 'ticker_sentiment_score': '0.191976', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.004185', 'ticker_sentiment_score': '0.191976', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NHPEF', 'relevance_score': '0.004185', 'ticker_sentiment_score': '0.039044', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.041835', 'ticker_sentiment_score': '-0.023792', 'ticker_sentiment_label': 'Neutral'}]"
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold - Merck & Co  ( NYSE:MRK ) ,20220920T152431,Merck & Co Inc MRK will initiate a new Phase 3 program with once-daily islatravir to treat people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir ( DOR/ISL ) .,"[{'ticker': 'GILD', 'relevance_score': '0.269776', 'ticker_sentiment_score': '-0.264301', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection,20220920T104731,Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences' lenacapavir to resume with lower dose of islatravir Monthly oral islatravir development for pre-exposure prophylaxis ( PrEP ) to be discontinued.,"[{'ticker': 'CURN', 'relevance_score': '0.035768', 'ticker_sentiment_score': '0.078442', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.035768', 'ticker_sentiment_score': '0.224553', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.035768', 'ticker_sentiment_score': '0.224553', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GILD', 'relevance_score': '0.035768', 'ticker_sentiment_score': '-0.086846', 'ticker_sentiment_label': 'Neutral'}]"
What This News Means for Merck,20221001T143000,Cancer drug Lynparza received an approval in China to treat patients with a type of ovarian cancer.,"[{'ticker': 'AZN', 'relevance_score': '0.186738', 'ticker_sentiment_score': '-0.209999', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
"AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know - iShares Biotechnology ETF  ( NASDAQ:IBB ) ",20221002T134945,"Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same ...","[{'ticker': 'FOLD', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SPPI', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.02666', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.121856', 'ticker_sentiment_score': '-0.105965', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BLUE', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.02666', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMLX', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.02666', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SUPN', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'YMAB', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.005154', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SCPH', 'relevance_score': '0.081414', 'ticker_sentiment_score': '-0.192203', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'RVNC', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.02666', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'THTX', 'relevance_score': '0.081414', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Posts Positive Results From PAH Drug Study,20221011T152700,Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.,"[{'ticker': 'UTHR', 'relevance_score': '0.256989', 'ticker_sentiment_score': '0.214467', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck's Patent Cliff Doesn't Look So Frightening Anymore,20221011T163300,Merck could be sitting on a blockbuster from a recent acquisition that would help reduce dependence on cancer drug Keytruda.,"[{'ticker': 'BMY', 'relevance_score': '0.331765', 'ticker_sentiment_score': '0.138952', 'ticker_sentiment_label': 'Neutral'}]"
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension - Investing News Network,20221010T105351,Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension Investing News Network ...,"[{'ticker': 'CURN', 'relevance_score': '0.032035', 'ticker_sentiment_score': '0.077888', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.032035', 'ticker_sentiment_score': '0.222063', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.032035', 'ticker_sentiment_score': '0.222063', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'BMY', 'relevance_score': '0.032035', 'ticker_sentiment_score': '0.145331', 'ticker_sentiment_label': 'Neutral'}]"
"New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Clene  ( NASDAQ:CLNN ) , Merck & Co  ( NYSE:MRK ) ",20221010T131852,People suffering from incurable neurological diseases such as multiple sclerosis ( MS ) and amyotrophic lateral sclerosis ( ALS ) hope new therapies and drugs will arrive sooner than later.,"[{'ticker': 'KTTA', 'relevance_score': '0.1871', 'ticker_sentiment_score': '0.210213', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SSTK', 'relevance_score': '0.047185', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CLNN', 'relevance_score': '0.094204', 'ticker_sentiment_score': '0.018949', 'ticker_sentiment_label': 'Neutral'}]"
Ginkgo Bioworks Announces Collaboration with Merck to Improve Active Pharmaceutical Ingredient Manufacturing,20221011T110000,Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes,"[{'ticker': 'APG', 'relevance_score': '0.078226', 'ticker_sentiment_score': '0.140893', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DNA', 'relevance_score': '0.078226', 'ticker_sentiment_score': '0.122356', 'ticker_sentiment_label': 'Neutral'}]"
Ginkgo Bioworks Announces Collaboration with Merck to Improve Active Pharmaceutical Ingredient Manufacturing,20221011T113833,Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes,"[{'ticker': 'APG', 'relevance_score': '0.078611', 'ticker_sentiment_score': '0.145126', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DNA', 'relevance_score': '0.078611', 'ticker_sentiment_score': '0.129662', 'ticker_sentiment_label': 'Neutral'}]"
Merck Stock Is Likely A Better Pick Over Its Peer,20221011T130000,"There is more to the comparison, and in the sections below, we discuss why we believe MRK stock will offer better returns than LLY stock in the next three years.","[{'ticker': 'LLY', 'relevance_score': '0.685243', 'ticker_sentiment_score': '0.378034', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'XYL', 'relevance_score': '0.042196', 'ticker_sentiment_score': '0.137902', 'ticker_sentiment_label': 'Neutral'}]"
Merck Collaborates Ginkgo Bioworks to Improve Active Pharmaceutical Ingredient Manufacturing - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ,20221011T154543,Ginkgo Bioworks Holdings Inc DNA collaborated with Merck & Co Inc MRK to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient ( API ) manufacturing efforts.,"[{'ticker': 'APG', 'relevance_score': '0.220809', 'ticker_sentiment_score': '0.151838', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DNA', 'relevance_score': '0.737923', 'ticker_sentiment_score': '0.474511', 'ticker_sentiment_label': 'Bullish'}]"
"Merck To Rally Over 29%? Here Are 5 Other Price Target Changes For Tuesday - Monolithic Power Systems  ( NASDAQ:MPWR ) , e.l.f. Beauty  ( NYSE:ELF ) ",20221011T114542,"Atlantic Equities raised Merck & Co., Inc. MRK price target from $110 to $116. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock. Merck shares fell 0.8% to $89.76 in pre-market trading. SVB Leerink cut the price target on Pfizer Inc. PFE from $53 to $48.","[{'ticker': 'ZM', 'relevance_score': '0.454174', 'ticker_sentiment_score': '-0.532383', 'ticker_sentiment_label': 'Bearish'}, {'ticker': 'TXRH', 'relevance_score': '0.454174', 'ticker_sentiment_score': '0.421069', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'MS', 'relevance_score': '0.31282', 'ticker_sentiment_score': '-0.423705', 'ticker_sentiment_label': 'Bearish'}, {'ticker': 'PFE', 'relevance_score': '0.454174', 'ticker_sentiment_score': '-0.21947', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Earnings Preview: Merck  ( MRK )  Q3 Earnings Expected to Decline,20221020T140220,Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,"[{'ticker': 'INVA', 'relevance_score': '0.173645', 'ticker_sentiment_score': '0.081733', 'ticker_sentiment_label': 'Neutral'}]"
Merck Stock In Bullish Setup Ahead Of Q3 Results; Apple Leads FAANG Earnings Barrage,20221021T151200,Merck Stock In Bullish Setup Ahead Of Q3 Results. Apple Leads FAANG Earnings Barrage Investor's Business Daily ...,"[{'ticker': 'NFLX', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.103231', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.033515', 'ticker_sentiment_score': '0.074533', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'META', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.079153', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'UAL', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.435167', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'AAPL', 'relevance_score': '0.231332', 'ticker_sentiment_score': '0.070465', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VRTX', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AAL', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.435167', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'DAL', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.435167', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'FSLR', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.107246', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DECK', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.107246', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LPLA', 'relevance_score': '0.100308', 'ticker_sentiment_score': '0.106659', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ISRG', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.103231', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TXRH', 'relevance_score': '0.06697', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
"Pfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia Vaccines",20221031T093300,"The growing $7 billion market is currently dominated by Pfizer, and rivals' interest in winning more of the business shows the pharmaceutical industry's renewed focus on vaccines.","[{'ticker': 'PCVX', 'relevance_score': '0.401331', 'ticker_sentiment_score': '-0.106232', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GSK', 'relevance_score': '0.401331', 'ticker_sentiment_score': '-0.106232', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.401331', 'ticker_sentiment_score': '-0.223215', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients - SELLAS Life Sciences Gr  ( NASDAQ:SLS ) ,20221110T160948,SELLAS Life Sciences Group Inc SLS announced confirmatory topline data from the final analysis of results from its Phase 1/2 trial of galinpepimut-S ( GPS ) . The trial assessed GPS in combination with Merck & Co Inc's MRK Keytruda ( pembrolizumab ) for WT1 ( + ) relapsed or refractory ...,"[{'ticker': 'BMY', 'relevance_score': '0.31282', 'ticker_sentiment_score': '0.119341', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SLS', 'relevance_score': '0.579393', 'ticker_sentiment_score': '-0.091613', 'ticker_sentiment_label': 'Neutral'}]"
"Meta Platforms, Hilton Grand Vacations, D.R. Horton, And Some Other Big Stocks Moving Higher On Wednesday - Array Technologies  ( NASDAQ:ARRY ) , A-Mark Precious Metals  ( NASDAQ:AMRK ) ",20221109T155421,"U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Wednesday. Here are some big stocks recording gains in today's session. Merrimack Pharmaceuticals, Inc. MACK shares climbed 219% to $12.80 after partner Ipsen reported Onivyde met its primary and key secondary endpoint.","[{'ticker': 'LTH', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.50564', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'META', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.081502', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'OPRX', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.371101', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'XPVVV', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.352661', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'ARRY', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.477221', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'AXON', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.301849', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ZD', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.50564', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'GFI', 'relevance_score': '0.2035', 'ticker_sentiment_score': '0.121263', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VVNT', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.404141', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'HCAT', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.241546', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'HCI', 'relevance_score': '0.136499', 'ticker_sentiment_score': '-0.208852', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'RAMP', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.477221', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'TH', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.126422', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HGV', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.436858', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'SEER', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.460001', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'SHLS', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.411181', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'AMRK', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.301849', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SFM', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.329423', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'HALO', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.301849', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SQSP', 'relevance_score': '0.2035', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'OM', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.301849', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MACK', 'relevance_score': '0.136499', 'ticker_sentiment_score': '-0.068326', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRC', 'relevance_score': '0.136499', 'ticker_sentiment_score': '0.50564', 'ticker_sentiment_label': 'Bullish'}]"
Drugmaker Merck to acquire Imago BioSciences for $1.35 bln,20221121T115300,Merck to Acquire Imago BioSciences for $1.35 billion ...,"[{'ticker': 'IMGO', 'relevance_score': '0.395012', 'ticker_sentiment_score': '-0.148779', 'ticker_sentiment_label': 'Neutral'}]"
Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer,20221121T121800,"Merck said it will pay $36 a share cash for Imago, which is developing drugs to treat bone-marrow diseases.","[{'ticker': 'IMGO', 'relevance_score': '0.451494', 'ticker_sentiment_score': '0.229676', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Imago BioSciences Stock Surges. It's Being Bought by Merck.,20221121T123000,"Merck announced Monday it would buy biopharmaceutical company Imago BioSciences in a deal valued at $1.35 billion. Pharmaceuticals giant Merck ( ticker: MRK ) will pay $36 in cash per share for Imago ( IMG ) , which is roughly double Imago's closing price of $17.40 a share on Friday.","[{'ticker': 'IMGO', 'relevance_score': '0.682689', 'ticker_sentiment_score': '0.539526', 'ticker_sentiment_label': 'Bullish'}]"
Why Imago BioSciences  ( IMGO )  Shares Are Soaring Today - Imago BioSciences  ( NASDAQ:IMGO ) ,20221121T135520,"Merck & Co Inc MRK has agreed to acquire Imago BioSciences Inc IMGO for $36.00 per share in cash for an approximate total equity value of $1.35 billion. ""This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,"" commented Merck's President & ...","[{'ticker': 'IMGO', 'relevance_score': '0.501398', 'ticker_sentiment_score': '0.530142', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'SGEN', 'relevance_score': '0.501398', 'ticker_sentiment_score': '0.235981', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Is Merck & Co.  ( MRK )  Outperforming Other Medical Stocks This Year?,20221121T144009,"Here is how Merck (MRK) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.","[{'ticker': 'CABA', 'relevance_score': '0.474958', 'ticker_sentiment_score': '0.148584', 'ticker_sentiment_label': 'Neutral'}]"
"Merck Buys A Biotech, But It's Not What Investors Expected",20221121T145500,Biotech Stock Imago Breaks Out To Record On $1.35 Billion Merck Buyout | Investor's Business Daily Investor's Business Daily ...,"[{'ticker': 'APLS', 'relevance_score': '0.080188', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.159569', 'ticker_sentiment_score': '-0.070162', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IMGO', 'relevance_score': '0.159569', 'ticker_sentiment_score': '-0.16231', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'BIIB', 'relevance_score': '0.080188', 'ticker_sentiment_score': '0.308024', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer - Marker Therapeutics  ( NASDAQ:MRKR ) ",20221122T120000,"HOUSTON, Nov. 22, 2022 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. MRKR, a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that ...","[{'ticker': 'MRKR', 'relevance_score': '0.246582', 'ticker_sentiment_score': '-0.036677', 'ticker_sentiment_label': 'Neutral'}]"
"XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon - XOMA  ( NASDAQ:XOMA ) ",20221122T120100,"XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475 million in development, regulatory, and sales milestones Low- to mid- teens royalties upon commercialization","[{'ticker': 'OBSV', 'relevance_score': '0.452384', 'ticker_sentiment_score': '0.3224', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'OGN', 'relevance_score': '0.3115', 'ticker_sentiment_score': '0.268933', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon",20221122T120100,"XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay ...","[{'ticker': 'OBSV', 'relevance_score': '0.33127', 'ticker_sentiment_score': '0.271812', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'OGN', 'relevance_score': '0.224556', 'ticker_sentiment_score': '0.209183', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Japan approves COVID antiviral pill as Pfizer, Merck alternative",20221122T122400,Japan approved an antiviral pill from Shionogi & Co. to treat Covid-19 after the company provided new data to show the drug's efficacy.,"[{'ticker': 'PFE', 'relevance_score': '0.355588', 'ticker_sentiment_score': '0.010196', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGIOF', 'relevance_score': '0.511256', 'ticker_sentiment_score': '0.084324', 'ticker_sentiment_label': 'Neutral'}]"
Merck Enters Definitive Agreement to Acquire Imago Biosciences | Financial Buzz,20221121T160707,Merck Enters Definitive Agreement to Acquire Imago Biosciences ...,"[{'ticker': 'BX', 'relevance_score': '0.143415', 'ticker_sentiment_score': '0.256618', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IMGO', 'relevance_score': '0.412298', 'ticker_sentiment_score': '0.500536', 'ticker_sentiment_label': 'Bullish'}]"
"Merck to Acquire Imago BioSciences, Inc. - Investing News Network",20221121T115400,"Merck to Acquire Imago BioSciences, Inc. Investing News Network ...","[{'ticker': 'CURN', 'relevance_score': '0.018965', 'ticker_sentiment_score': '0.034637', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.018965', 'ticker_sentiment_score': '0.2074', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.03792', 'ticker_sentiment_score': '0.110333', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BX', 'relevance_score': '0.018965', 'ticker_sentiment_score': '0.187196', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IMGO', 'relevance_score': '0.094613', 'ticker_sentiment_score': '0.114415', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MS', 'relevance_score': '0.018965', 'ticker_sentiment_score': '0.060558', 'ticker_sentiment_label': 'Neutral'}]"
New Strong Buy Stocks for November 21st,20221121T132400,"AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.","[{'ticker': 'ACR', 'relevance_score': '0.492659', 'ticker_sentiment_score': '0.274583', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'H', 'relevance_score': '0.492659', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMRK', 'relevance_score': '0.259727', 'ticker_sentiment_score': '0.208442', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ENTX', 'relevance_score': '0.492659', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EDAP', 'relevance_score': '0.492659', 'ticker_sentiment_score': '-0.207141', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
"Imago BioSciences, GrafTech International And Some Other Big Stocks Moving Higher On Monday - Belite Bio  ( NASDAQ:BLTE ) , Walt Disney  ( NYSE:DIS ) ",20221121T162705,"U.S. stocks traded lower, with the Dow Jones dropping around 70 points on Monday. Here are some big stocks recording gains in today's session. Imago BioSciences, Inc. IMGO shares jumped 104% to $35.50 after Merck announced it would acquire the company for $36 per share in cash.","[{'ticker': 'GBIO', 'relevance_score': '0.382925', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HUMA', 'relevance_score': '0.261117', 'ticker_sentiment_score': '-0.050725', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BLTE', 'relevance_score': '0.382925', 'ticker_sentiment_score': '0.20524', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PEPG', 'relevance_score': '0.261117', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EAF', 'relevance_score': '0.261117', 'ticker_sentiment_score': '0.239188', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'HRT', 'relevance_score': '0.382925', 'ticker_sentiment_score': '0.440927', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'CCORF', 'relevance_score': '0.132368', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IMGO', 'relevance_score': '0.261117', 'ticker_sentiment_score': '0.351634', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'DIS', 'relevance_score': '0.261117', 'ticker_sentiment_score': '0.363926', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'SHC', 'relevance_score': '0.382925', 'ticker_sentiment_score': '-0.15714', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'BCS', 'relevance_score': '0.132368', 'ticker_sentiment_score': '-0.072086', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MMAT', 'relevance_score': '0.261117', 'ticker_sentiment_score': '0.292514', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'XAIR', 'relevance_score': '0.382925', 'ticker_sentiment_score': '-0.013771', 'ticker_sentiment_label': 'Neutral'}]"
"Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer",20221129T130000,"SYDNEY, AUSTRALIA, Nov. 29, 2022 ( GLOBE NEWSWIRE ) -- Immutep Limited ( ASX: IMM. NASDAQ: IMMP ) ( ""Immutep"" or ""the Company"" ) , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial ...","[{'ticker': 'IMMP', 'relevance_score': '0.290361', 'ticker_sentiment_score': '0.061774', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.126784', 'ticker_sentiment_score': '-0.081418', 'ticker_sentiment_label': 'Neutral'}]"
MRK: Is Merck & Co. Stock Worth Buying Before the End of 2022?,20221129T141547,"Healthcare stalwart Merck & Co., Inc. ( MRK ) continues to strive toward developing its pipeline through acquisitions. The company recently announced that it would acquire clinical-stage biopharmaceutical company Imago BioSciences, Inc. ( IMGO ) for an approximate total equity value of $1.35 ...","[{'ticker': 'IMGO', 'relevance_score': '0.109705', 'ticker_sentiment_score': '0.050152', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.109705', 'ticker_sentiment_score': '0.090712', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.109705', 'ticker_sentiment_score': '0.090712', 'ticker_sentiment_label': 'Neutral'}]"
Visa Stock Builds A Base Of Core Institutional Owners As Holiday Sales Start,20221129T201500,"In Tuesday's IBD Screen of the Day, the focus is on top stocks that mutual funds are increasing their stakes in. Let's focus on Visa ( V ) , which pops up on our screen of 41 high-ranking stocks as the third-ranked stock, behind pharmaceutical giants Eli Lilly ( LLY ) and Merck ( MRK ) .","[{'ticker': 'LLY', 'relevance_score': '0.141726', 'ticker_sentiment_score': '0.046471', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CASS', 'relevance_score': '0.141726', 'ticker_sentiment_score': '0.104315', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SPGI', 'relevance_score': '0.071145', 'ticker_sentiment_score': '0.195436', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MA', 'relevance_score': '0.071145', 'ticker_sentiment_score': '0.085438', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'V', 'relevance_score': '0.628066', 'ticker_sentiment_score': '0.193049', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Stryker, Freeport-McMoRan, Southwest Gas And This Health Care Major Feature On CNBC's 'Final Trades' - Merck & Co  ( NYSE:MRK ) , Freeport-McMoRan  ( NYSE:FCX ) ",20221209T133029,"On CNBC's ""Halftime Report Final Trades,"" Brenda Vingiello of Sand Hill Global Advisors chose Stryker Corporation SYK, saying all medical procedures that are in backlog should be completed over the next couple of years. ""[It's] really poised to benefit from that,"" she added.","[{'ticker': 'SYK', 'relevance_score': '0.490323', 'ticker_sentiment_score': '0.360688', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'SWX', 'relevance_score': '0.490323', 'ticker_sentiment_score': '0.25355', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'FCX', 'relevance_score': '0.490323', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns,20221212T133500,"Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.","[{'ticker': 'MCK', 'relevance_score': '0.230017', 'ticker_sentiment_score': '0.200027', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'VRTX', 'relevance_score': '0.139265', 'ticker_sentiment_score': '0.102835', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSGR', 'relevance_score': '0.093108', 'ticker_sentiment_score': '0.159496', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck Begins Tender Offer to Acquire Imago BioSciences, Inc. - Investing News Network",20221212T153236,"Merck Begins Tender Offer to Acquire Imago BioSciences, Inc. Investing News Network ...","[{'ticker': 'CURN', 'relevance_score': '0.030918', 'ticker_sentiment_score': '0.03627', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.030918', 'ticker_sentiment_score': '0.223222', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.030918', 'ticker_sentiment_score': '0.223222', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IMGO', 'relevance_score': '0.06179', 'ticker_sentiment_score': '0.136046', 'ticker_sentiment_label': 'Neutral'}]"
"Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & Deere",20221209T182500,"Today's Research Daily features update on the Q4 earnings season and new research reports on Merck (MRK), Bristol-Myers (BMY) and Deere (DE).","[{'ticker': 'DE', 'relevance_score': '0.182506', 'ticker_sentiment_score': '0.170352', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'COST', 'relevance_score': '0.137409', 'ticker_sentiment_score': '-0.002444', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ACN', 'relevance_score': '0.046006', 'ticker_sentiment_score': '0.05106', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LEN', 'relevance_score': '0.046006', 'ticker_sentiment_score': '0.05106', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZO', 'relevance_score': '0.137409', 'ticker_sentiment_score': '-0.002444', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.182506', 'ticker_sentiment_score': '0.170352', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere",20221212T093000,"Merck, Bristol-Myers Squibb and Deere are included in this Analyst Blog.","[{'ticker': 'DE', 'relevance_score': '0.165031', 'ticker_sentiment_score': '0.230406', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'COST', 'relevance_score': '0.165031', 'ticker_sentiment_score': '-0.002735', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ACN', 'relevance_score': '0.055364', 'ticker_sentiment_score': '0.052873', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LEN', 'relevance_score': '0.055364', 'ticker_sentiment_score': '0.052873', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZO', 'relevance_score': '0.218817', 'ticker_sentiment_score': '-0.003374', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.165031', 'ticker_sentiment_score': '0.141253', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant",20221219T125300,"Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.","[{'ticker': 'IMVT', 'relevance_score': '0.279927', 'ticker_sentiment_score': '0.134289', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VRTX', 'relevance_score': '0.162255', 'ticker_sentiment_score': '0.078459', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IMCR', 'relevance_score': '0.202028', 'ticker_sentiment_score': '0.10648', 'ticker_sentiment_label': 'Neutral'}]"
"Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings - AstraZeneca  ( NASDAQ:AZN ) , AstraZeneca  ( OTC:AZNCF ) ",20221221T131738,The European Commission has approved AstraZeneca Plc AZN and Merck & Co Inc's MRK Lynparza ( olaparib ) plus abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer ( mCRPC ) for patients for whom chemotherapy is not clinically indicated.,"[{'ticker': 'AZN', 'relevance_score': '0.695767', 'ticker_sentiment_score': '-0.264356', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Could This Opportunity Make Moderna a Hot Buy Again?,20221221T143700,Merck and Moderna recently announced positive results from a trial involving their personalized cancer vaccine.,"[{'ticker': 'MRNA', 'relevance_score': '0.720006', 'ticker_sentiment_score': '0.043375', 'ticker_sentiment_label': 'Neutral'}]"
"Merck  ( MRK ) , Seagen Keytruda-Padcev sBLAs Get FDA Priority Tag",20221221T152200,Merck (MRK) and Seagen's (SGEN) sBLAs seek approval of Padcev plus Keytruda for locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing chemotherapy.,"[{'ticker': 'ALPMF', 'relevance_score': '0.090134', 'ticker_sentiment_score': '0.057749', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.179121', 'ticker_sentiment_score': '0.071114', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.428632', 'ticker_sentiment_score': '-0.043855', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.265859', 'ticker_sentiment_score': '0.120181', 'ticker_sentiment_label': 'Neutral'}]"
"After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm - NGM Biopharmaceuticals  ( NASDAQ:NGM ) , Merck & Co  ( NYSE:MRK ) ",20221221T153407,Merck & Co Inc MRK has notified NGM Biopharmaceuticals Inc NGM that it will not exercise its option to license NGM621 and its related compounds. Merck will also not exercise the related ophthalmology bundle option.,"[{'ticker': 'NGM', 'relevance_score': '0.885652', 'ticker_sentiment_score': '0.115089', 'ticker_sentiment_label': 'Neutral'}]"
"After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm",20221221T153408,"After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With ...","[{'ticker': 'NGM', 'relevance_score': '0.846873', 'ticker_sentiment_score': '0.109282', 'ticker_sentiment_label': 'Neutral'}]"
"Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer",20221220T115316,"This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting - Seagen Inc. ( Nasdaq: SGEN ) , Astellas Pharma Inc. ( TSE:4503 ) and Merck ( NYSE: MRK ) , known as MSD outside of the United States and ...","[{'ticker': 'ALPMF', 'relevance_score': '0.017541', 'ticker_sentiment_score': '-0.027889', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CURN', 'relevance_score': '0.008771', 'ticker_sentiment_score': '0.062955', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.004386', 'ticker_sentiment_score': '0.192254', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.004386', 'ticker_sentiment_score': '0.192254', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NHPEF', 'relevance_score': '0.004386', 'ticker_sentiment_score': '0.039102', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.043834', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
LYNPARZA® in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer,20221221T120446,"AstraZeneca and Merck ( NYSE: MRK ) , known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved in the European Union ( EU ) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic ...","[{'ticker': 'CURN', 'relevance_score': '0.010393', 'ticker_sentiment_score': '0.071083', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.010393', 'ticker_sentiment_score': '0.197419', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.010393', 'ticker_sentiment_score': '0.197419', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NHPEF', 'relevance_score': '0.010393', 'ticker_sentiment_score': '0.012773', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.082999', 'ticker_sentiment_score': '0.050813', 'ticker_sentiment_label': 'Neutral'}]"
MRK: New to Investing? Give These 2 Robust Stocks a Try,20221221T162544,"The stock market has witnessed wild swings lately, with slowing inflation and the Fed's hawkish tone influencing investors. However, many experts believe the stock market will stabilize next year despite the possibility of a recession.","[{'ticker': 'VZ', 'relevance_score': '0.403264', 'ticker_sentiment_score': '0.219043', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IMGO', 'relevance_score': '0.084275', 'ticker_sentiment_score': '0.175637', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'WIT', 'relevance_score': '0.126119', 'ticker_sentiment_score': '0.031147', 'ticker_sentiment_label': 'Neutral'}]"
"China COVID cases could double next month, as Merck antiviral gets approval",20221230T095000,China's health service approved an antiviral to treat COVID-19 as one health company estimates the country will see a doubling of its current wave of cases.,"[{'ticker': 'PFE', 'relevance_score': '0.443626', 'ticker_sentiment_score': '0.093776', 'ticker_sentiment_label': 'Neutral'}]"
"PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany - PDS Biotechnology  ( NASDAQ:PDSB ) ",20230103T120000,"PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at 8:00 AM EST","[{'ticker': 'PDSB', 'relevance_score': '0.084498', 'ticker_sentiment_score': '0.046699', 'ticker_sentiment_label': 'Neutral'}]"
"PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment - PDS Biotechnology  ( NASDAQ:PDSB ) ",20230103T161350,"PDS Biotechnology Corporation PDSB announced an exclusive global license agreement with Merck KGaA MKGAF MKKGY for the tumor-targeting IL-12 fusion protein M9241 ( formerly known as NHS-IL12 ) , which will join the pipeline as PDS0301.","[{'ticker': 'PDSB', 'relevance_score': '0.694939', 'ticker_sentiment_score': '0.545721', 'ticker_sentiment_label': 'Bullish'}]"
"Analyst Upgrades Merck To Buy, Downgrades Pfizer To Neutral - Merck & Co  ( NYSE:MRK ) ",20230104T182233,"The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be a volatile 2023.","[{'ticker': 'BAC', 'relevance_score': '0.119235', 'ticker_sentiment_score': '0.080038', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.63188', 'ticker_sentiment_score': '0.227112', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Top Analyst Reports for Home Depot, Merck & Bank of America",20230110T173700,"Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Merck & Co., Inc. (MRK) and Bank of America Corporation (BAC).","[{'ticker': 'RMD', 'relevance_score': '0.111488', 'ticker_sentiment_score': '0.185503', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'BAC', 'relevance_score': '0.325924', 'ticker_sentiment_score': '0.245987', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'HD', 'relevance_score': '0.325924', 'ticker_sentiment_score': '0.205306', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IBM', 'relevance_score': '0.111488', 'ticker_sentiment_score': '0.185503', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ELV', 'relevance_score': '0.111488', 'ticker_sentiment_score': '0.185503', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer,20230118T123000,"Company Adds Former Executive at Takeda, Pfizer, AstraZeneca, GSK and Merck to Leadership Team Company Adds Former Executive at Takeda, Pfizer, AstraZeneca, GSK and Merck to Leadership Team ...","[{'ticker': 'REUN', 'relevance_score': '0.135602', 'ticker_sentiment_score': '0.165847', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AZN', 'relevance_score': '0.045396', 'ticker_sentiment_score': '-0.06577', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.045396', 'ticker_sentiment_score': '-0.06577', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TSOI', 'relevance_score': '0.090645', 'ticker_sentiment_score': '0.11117', 'ticker_sentiment_label': 'Neutral'}]"
MRK: The 3 Best Large-Cap Stocks to Buy Now and Hold Forever,20230119T181001,"With a slowdown in inflation strengthening speculation that the Federal Reserve is nearing the end of its interest-rate-hike cycle, investors expect a breather from the turmoil that kept markets under pressure last year. In addition, the employment data showed that growth continues to hold up ...","[{'ticker': 'MOR', 'relevance_score': '0.059935', 'ticker_sentiment_score': '0.105242', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TAP', 'relevance_score': '0.059935', 'ticker_sentiment_score': '0.215064', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'KO', 'relevance_score': '0.207571', 'ticker_sentiment_score': '0.219024', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'JPM', 'relevance_score': '0.059935', 'ticker_sentiment_score': '-0.143007', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVS', 'relevance_score': '0.348103', 'ticker_sentiment_score': '0.260872', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IMGO', 'relevance_score': '0.089797', 'ticker_sentiment_score': '0.189215', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ERAS', 'relevance_score': '0.089797', 'ticker_sentiment_score': '0.201988', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck  ( MRK )  to Report Q4 Earnings: What's in the Cards?,20230130T130500,"Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.","[{'ticker': 'AZN', 'relevance_score': '0.194242', 'ticker_sentiment_score': '0.112211', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.194242', 'ticker_sentiment_score': '0.052785', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.241444', 'ticker_sentiment_score': '-0.027473', 'ticker_sentiment_label': 'Neutral'}]"
A-Mark Precious Metals  ( NASDAQ:AMRK )  Downgraded by StockNews.com to Hold,20230208T084241,A-Mark Precious Metals ( NASDAQ:AMRK ) Downgraded by ... Armenian Reporter ...,"[{'ticker': 'AMRK', 'relevance_score': '0.702224', 'ticker_sentiment_score': '0.4473', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'HTZ', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.137853', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VCNX', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.137853', 'ticker_sentiment_label': 'Neutral'}]"
A-Mark Precious Metals  ( NASDAQ:AMRK )  Downgraded by StockNews.com to Hold,20230208T084247,A-Mark Precious Metals ( NASDAQ:AMRK ) Downgraded by ... Defense World ...,"[{'ticker': 'AMRK', 'relevance_score': '0.702224', 'ticker_sentiment_score': '0.4473', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'HTZ', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.137853', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VCNX', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.137853', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Gets Priority Tag for Antiviral Drug Prevymis sNDA,20230220T133800,"The FDA grants priority review designation to Merck's (MRK) sNDA seeking expanded use of Prevymis. The PDUFA date is Jun 5, 2023.","[{'ticker': 'NVO', 'relevance_score': '0.552443', 'ticker_sentiment_score': '0.251291', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Analyst Cautions Investors On Overreacting To 'Early-Stage' Pfizer/Seagen Discussions - Seagen  ( NASDAQ:SGEN ) , Pfizer  ( NYSE:PFE ) ",20230227T174308,"In a news article by the Wall Street Journal, Pfizer Inc PFE is reportedly in early-stage talks to acquire Seagen Inc SGEN for over $30 billion. In June last year, the Wall Street Journal reported that Merck & Co Inc MRK showed interest in buying Seagen.","[{'ticker': 'PFE', 'relevance_score': '0.433523', 'ticker_sentiment_score': '0.093171', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.74841', 'ticker_sentiment_score': '0.464749', 'ticker_sentiment_label': 'Bullish'}]"
Merck's scraps another prostate cancer study as Keytruda therapy disappoints,20230228T125000,Merck's scraps another prostate cancer study as Keytruda therapy ... ...,"[{'ticker': 'ALPMF', 'relevance_score': '0.141726', 'ticker_sentiment_score': '-0.04752', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.141726', 'ticker_sentiment_score': '-0.04752', 'ticker_sentiment_label': 'Neutral'}]"
Merck Stock Looks Better Priced Compared To Its Sector Peer,20230228T110042,"Although investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential, we believe this gap will narrow in favor of Merck.","[{'ticker': 'LLY', 'relevance_score': '0.741581', 'ticker_sentiment_score': '0.441575', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'XYL', 'relevance_score': '0.040969', 'ticker_sentiment_score': '0.14184', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK",20230310T122300,FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.,"[{'ticker': 'LLY', 'relevance_score': '0.275867', 'ticker_sentiment_score': '-0.093598', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.112269', 'ticker_sentiment_score': '-0.162572', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'SNY', 'relevance_score': '0.167709', 'ticker_sentiment_score': '-0.014208', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK",20230310T132300,FDA accepts Sanofi's (SNY) Dupixent sBLA. Lilly's (LLY) solanezumab fails to prevent Alzheimer's in a study.,"[{'ticker': 'LLY', 'relevance_score': '0.275867', 'ticker_sentiment_score': '-0.093598', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.112269', 'ticker_sentiment_score': '-0.162572', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'SNY', 'relevance_score': '0.167709', 'ticker_sentiment_score': '-0.014208', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Stock Up 31.6% in a Year: What Awaits in 2023?,20230320T102600,Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.,"[{'ticker': 'LGND', 'relevance_score': '0.184951', 'ticker_sentiment_score': '0.028901', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.046633', 'ticker_sentiment_score': '0.048995', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.184951', 'ticker_sentiment_score': '-0.078033', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.139265', 'ticker_sentiment_score': '0.052105', 'ticker_sentiment_label': 'Neutral'}]"
"A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ",20230320T131548,"With the COVID pandemic still ongoing, having claimed more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and development related to the COVID virus remains highly relevant and necessary.","[{'ticker': 'TRMNF', 'relevance_score': '0.048621', 'ticker_sentiment_score': '0.097058', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVAX', 'relevance_score': '0.097062', 'ticker_sentiment_score': '-0.023839', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.097062', 'ticker_sentiment_score': '-0.023839', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.097062', 'ticker_sentiment_score': '-0.023839', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.192694', 'ticker_sentiment_score': '-0.04682', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BNTX', 'relevance_score': '0.048621', 'ticker_sentiment_score': '-0.021984', 'ticker_sentiment_label': 'Neutral'}]"
Why OncoSec Medical  ( ONCS )  Shares Are Plunging Today - OncoSec Medical  ( NASDAQ:ONCS ) ,20230403T154212,"OncoSec Medical Incorporated ONCS shares plummeted Monday following Phase 2 KEYNOTE-695 clinical trial data. The primary endpoint of the overall response rate ( ORR ) was not met. The company evaluated TAVO-EP, in combination with Merck & Co Inc MRK Keytruda ( pembrolizumab ) in unresectable ...","[{'ticker': 'ONCS', 'relevance_score': '0.443626', 'ticker_sentiment_score': '0.292292', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Pfizer, Merck trim prices in China for Paxlovid, molnupiravir - reports",20230404T094500,"SHANGHAI, April 4 ( Reuters ) - Pfizer ( PFE.N ) and Merck ( MRK.N ) have slightly lowered the prices of their respective Paxlovid and molnupiravir COVID-19 treatments in China, local media reported on Tuesday citing pricing information published by the province of Jiangsu.","[{'ticker': 'PFE', 'relevance_score': '0.507107', 'ticker_sentiment_score': '-0.107992', 'ticker_sentiment_label': 'Neutral'}]"
"After Denying Earlier, Pfizer & Merck Marginally Cut Prices For COVID-19 Treatments In China - Merck & Co  ( NYSE:MRK ) , Pfizer  ( NYSE:PFE ) ",20230404T130658,Pfizer Inc PFE and Merck & Co Inc MRK have reportedly lowered the prices of their respective COVID-19 treatments in China.,"[{'ticker': 'PFE', 'relevance_score': '0.716023', 'ticker_sentiment_score': '0.003822', 'ticker_sentiment_label': 'Neutral'}]"
"FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer - Astellas Pharma  ( OTC:ALPMY ) , Merck & Co  ( NYSE:MRK ) , Astellas Pharma  ( OTC:ALPMF ) ",20230404T130850,The FDA approved Merck & Co Inc's MRK Keytruda ( pembrolizumab ) in combination with Astellas Pharma Inc ALMPF & Seagen Inc's SGEN Padcev ( enfortumab vedotin-ejfv ) locally advanced or metastatic urothelial carcinoma ( la/mUC ) who are not eligible for cisplatin-containing chemotherapy.,"[{'ticker': 'ALPMF', 'relevance_score': '0.157483', 'ticker_sentiment_score': '0.139954', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.573213', 'ticker_sentiment_score': '0.347869', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck  ( MRK ) , Seagen Drug Combo Gets FDA Nod for Bladder Cancer",20230404T141700,The combination of Merck's (MRK) Keytruda and Seagen's (SGEN) Padcev is the first approved immunotherapy and an antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma.,"[{'ticker': 'ALPMF', 'relevance_score': '0.083251', 'ticker_sentiment_score': '0.063232', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.324139', 'ticker_sentiment_score': '0.176772', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SGEN', 'relevance_score': '0.246167', 'ticker_sentiment_score': '0.053059', 'ticker_sentiment_label': 'Neutral'}]"
Seagen's  ( SGEN )  Padcev & Keytruda Combo Gets FDA Accelerated Nod,20230404T150500,"The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.","[{'ticker': 'ADMA', 'relevance_score': '0.261818', 'ticker_sentiment_score': '0.119751', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ALPMF', 'relevance_score': '0.066598', 'ticker_sentiment_score': '0.047333', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.496201', 'ticker_sentiment_score': '0.032156', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'APTX', 'relevance_score': '0.261818', 'ticker_sentiment_score': '0.082762', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Keytruda Studies in Difficult-to-Treat Cancers Fail,20230410T123800,Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.,"[{'ticker': 'INVA', 'relevance_score': '0.283542', 'ticker_sentiment_score': '0.092515', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'APTX', 'relevance_score': '0.283542', 'ticker_sentiment_score': '0.077486', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.22861', 'ticker_sentiment_score': '0.086362', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.283542', 'ticker_sentiment_score': '0.150568', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer",20230410T125500,"J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.","[{'ticker': 'AZN', 'relevance_score': '0.235823', 'ticker_sentiment_score': '-0.015107', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.095517', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.142847', 'ticker_sentiment_score': '0.058771', 'ticker_sentiment_label': 'Neutral'}]"
"Zacks Investment Ideas feature highlights: Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical",20230410T121700,"Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical are part of the Zacks Investment Ideas article.","[{'ticker': 'ISRG', 'relevance_score': '0.254751', 'ticker_sentiment_score': '0.130995', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVDA', 'relevance_score': '0.33514', 'ticker_sentiment_score': '0.107571', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.254751', 'ticker_sentiment_score': '0.130995', 'ticker_sentiment_label': 'Neutral'}]"
"Moderna  ( MRNA ) , Merck's Cancer Jab Gets EMA's PRIME Tag",20230410T151200,The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.,"[{'ticker': 'MRNA', 'relevance_score': '0.513698', 'ticker_sentiment_score': '0.081562', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.050465', 'ticker_sentiment_score': '0.161923', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'CERT', 'relevance_score': '0.248343', 'ticker_sentiment_score': '0.053093', 'ticker_sentiment_label': 'Neutral'}]"
How to Tell Biotech's Likely Winners From Losers,20230418T120000,A discerning approach is warranted even as Merck lifts the sector with a deal for a company without any approved products.,"[{'ticker': 'RXDX', 'relevance_score': '0.514619', 'ticker_sentiment_score': '0.225364', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?,20230419T144500,Merck's move into immunology is a risky proposition.,"[{'ticker': 'RXDX', 'relevance_score': '0.143415', 'ticker_sentiment_score': '0.148525', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.282234', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.072', 'ticker_sentiment_score': '0.03238', 'ticker_sentiment_label': 'Neutral'}]"
"TSLA, WINT, ENVX, MRNA, BLBX: Top 5 Trending Stocks - Netflix  ( NASDAQ:NFLX ) , Windtree Therapeutics  ( NASDAQ:WINT ) , Tesla  ( NASDAQ:TSLA ) , Morgan Stanley  ( NYSE:MS ) , Merck & Co  ( NYSE:MRK ) , Enovix  ( NASDAQ:ENVX ) , Moderna  ( NASDAQ:MRNA ) , Blackboxstocks  ( NASDAQ:BLBX ) ",20230418T011313,"U.S. markets ended in the green on Monday, supported by financial and industrial stocks. Investors and traders are watching out for a slew of corporate earnings this week that include big names like Tesla Inc TSLA, Netflix Inc NFLX and Morgan Stanley MS.","[{'ticker': 'NFLX', 'relevance_score': '0.223866', 'ticker_sentiment_score': '0.094462', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'WINT', 'relevance_score': '0.223866', 'ticker_sentiment_score': '0.223714', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'TSLA', 'relevance_score': '0.430454', 'ticker_sentiment_score': '0.258043', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MS', 'relevance_score': '0.223866', 'ticker_sentiment_score': '0.094462', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ENVX', 'relevance_score': '0.330286', 'ticker_sentiment_score': '-0.004726', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.223866', 'ticker_sentiment_score': '-0.255208', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'BLBX', 'relevance_score': '0.223866', 'ticker_sentiment_score': '-0.039002', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study",20230428T164700,"Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.","[{'ticker': 'AZN', 'relevance_score': '0.105449', 'ticker_sentiment_score': '0.06709', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.035241', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LLY', 'relevance_score': '0.309107', 'ticker_sentiment_score': '0.116556', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMPH', 'relevance_score': '0.035241', 'ticker_sentiment_score': '0.017565', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.105449', 'ticker_sentiment_score': '0.033014', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.070414', 'ticker_sentiment_score': '-0.070296', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.105449', 'ticker_sentiment_score': '0.092897', 'ticker_sentiment_label': 'Neutral'}]"
"FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug - AstraZeneca  ( NASDAQ:AZN ) , AstraZeneca  ( OTC:AZNCF ) , Merck & Co  ( NYSE:MRK ) ",20230501T102007,The FDA's Oncologic Drugs Advisory Committee ( ODAC ) voted against AstraZeneca Plc AZN and Merck & Co Inc's MRK application seeking approval for expanded use of Lynparza ( olaparib ) to all adult patients with metastatic castration-resistant prostate cancer ( mCRPC ) .,"[{'ticker': 'AZN', 'relevance_score': '0.576289', 'ticker_sentiment_score': '0.111372', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Q1 2023 Earnings Call Transcript,20230428T193456,"MRK earnings call for the period ending March 31, 2023.","[{'ticker': 'EVR', 'relevance_score': '0.004993', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BCS', 'relevance_score': '0.004993', 'ticker_sentiment_score': '0.180219', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'C', 'relevance_score': '0.009986', 'ticker_sentiment_score': '0.066496', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.004993', 'ticker_sentiment_score': '0.106785', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MS', 'relevance_score': '0.004993', 'ticker_sentiment_score': '0.139769', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.009986', 'ticker_sentiment_score': '0.116639', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GS', 'relevance_score': '0.004993', 'ticker_sentiment_score': '0.164768', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MRNA', 'relevance_score': '0.03494', 'ticker_sentiment_score': '0.124316', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RXDX', 'relevance_score': '0.004993', 'ticker_sentiment_score': '0.246826', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - Marker Therapeutics  ( NASDAQ:MRKR ) ",20230508T113004,"HOUSTON, May 08, 2023 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. MRKR, a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of ...","[{'ticker': 'MRKR', 'relevance_score': '0.338913', 'ticker_sentiment_score': '0.098089', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GERN', 'relevance_score': '0.099683', 'ticker_sentiment_score': '0.066749', 'ticker_sentiment_label': 'Neutral'}]"
Here's Why Merck  ( MRK )  Stock Has Outperformed Industry YTD,20230518T143800,Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.,"[{'ticker': 'MRNA', 'relevance_score': '0.149966', 'ticker_sentiment_score': '0.050572', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RXDX', 'relevance_score': '0.100308', 'ticker_sentiment_score': '0.137434', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.149966', 'ticker_sentiment_score': '-0.002584', 'ticker_sentiment_label': 'Neutral'}]"
Is Merck Stock A Better Pick Over ABBV?,20230601T120000,"There is more to the comparison, and in the sections below, we discuss why we believe ABBV stock will offer higher returns than MRK stock in the next three years.","[{'ticker': 'ABBV', 'relevance_score': '0.716023', 'ticker_sentiment_score': '0.363885', 'ticker_sentiment_label': 'Bullish'}]"
Drug Maker Merck Sues US Gov. Over Inflation Reduction Act,20230607T010013,The war on drug prices faces a counter-offensive. While many pharmaceutical companies have been moaning and groaning about the new regulations on...,"[{'ticker': 'PFE', 'relevance_score': '0.075874', 'ticker_sentiment_score': '-0.064996', 'ticker_sentiment_label': 'Neutral'}]"
Merck lawsuit opens new effort to cripple drug price negotiations,20230607T093000,"Merck's lawsuit challenging drug price negotiations established by the Inflation Reduction Act is the likely start of a flurry of litigation to undo Democrats' signature effort to tackle pharmaceutical costs. Why it matters: At a minimum, the IRA's drug pricing provisions probably won't start on ...","[{'ticker': 'BIIB', 'relevance_score': '0.069697', 'ticker_sentiment_score': '-0.070655', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Sues US Government to Halt Drug Price Negotiations,20230607T180100,Merck (MRK) files a lawsuit against claiming that the federal government is violating the Constitution by forcing drugmakers to negotiate prices at below market rates.,"[{'ticker': 'NVO', 'relevance_score': '0.259037', 'ticker_sentiment_score': '0.162804', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PFE', 'relevance_score': '0.195814', 'ticker_sentiment_score': '-0.089661', 'ticker_sentiment_label': 'Neutral'}]"
Merck's  ( MRK )  Keytruda for Liver Cancer to Undergo FDA Review,20230609T145200,FDA accepts Merck's (MRK) supplemental biologics license application for Keytruda plus chemotherapy for the treatment of patients with first-line advanced or metastatic biliary tract cancer.,"[{'ticker': 'ADAP', 'relevance_score': '0.327366', 'ticker_sentiment_score': '0.11075', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.275246', 'ticker_sentiment_score': '0.188591', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Is Merck Stock a Top Buy Right Now?,20230619T131500,The drugmaker is still a work in progress.,"[{'ticker': 'RXDX', 'relevance_score': '0.063763', 'ticker_sentiment_score': '0.009021', 'ticker_sentiment_label': 'Neutral'}]"
Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co.  ( MRK ) ,20230619T233434,"Warren Buffett states, ""Uncertainty is the friend of the buyer of long-term values,"" and Washington represents a big question mark these days for the pharma sector.","[{'ticker': 'GILD', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.033', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.103554', 'ticker_sentiment_score': '0.006637', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.033', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.051886', 'ticker_sentiment_score': '-0.232646', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'JNJ', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.033', 'ticker_sentiment_label': 'Neutral'}]"
Merck's  ( MRK )  Gastric Cancer Study Fails to Meet a Primary Goal,20230621T144600,Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.,"[{'ticker': 'ADMA', 'relevance_score': '0.288044', 'ticker_sentiment_score': '0.012778', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AKRO', 'relevance_score': '0.288044', 'ticker_sentiment_score': '-0.05349', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'OMGA', 'relevance_score': '0.218161', 'ticker_sentiment_score': '0.010217', 'ticker_sentiment_label': 'Neutral'}]"
"Merck, Ridgeback Withdraw COVID-19 Pill European Application Amid Regulatory Hurdles - Merck & Co  ( NYSE:MRK ) ",20230627T180645,Merck & Co Inc MRK and Ridgeback Biotherapeutics have reportedly withdrawn their COVID-19 pill application in the European Union ( EU ) . The withdrawal came after the European Medicines Agency cited insufficient data for not backing the drug.,"[{'ticker': 'PFE', 'relevance_score': '0.316846', 'ticker_sentiment_score': '0.36248', 'ticker_sentiment_label': 'Bullish'}]"
"Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys",20230703T131500,"Both companies are facing significant patent cliffs, but they've been preparing for this moment.","[{'ticker': 'ABBV', 'relevance_score': '0.331765', 'ticker_sentiment_score': '0.202738', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ABT', 'relevance_score': '0.04882', 'ticker_sentiment_score': '0.156967', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'RXDX', 'relevance_score': '0.04882', 'ticker_sentiment_score': '0.104947', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.04882', 'ticker_sentiment_score': '-0.001', 'ticker_sentiment_label': 'Neutral'}]"
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients,20230710T110000,"HOUSTON, July 10, 2023 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced that ...","[{'ticker': 'MRKR', 'relevance_score': '0.231332', 'ticker_sentiment_score': '0.114089', 'ticker_sentiment_label': 'Neutral'}]"
"Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials - What Other Viruses Could This COVID Treatment Target? - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ",20230710T131314,"NanoViricides NNVC has begun trials for its new drug candidate, NV-CoV-2 - an exciting development for the biotech company, as it starts its first human trials with drug sponsor Karveer Meditech Pvt. Ltd. India, the company's licensee and co-developer in India.","[{'ticker': 'PFE', 'relevance_score': '0.099271', 'ticker_sentiment_score': '-0.045466', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.099271', 'ticker_sentiment_score': '-0.045466', 'ticker_sentiment_label': 'Neutral'}]"
"The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck",20230718T131500,"The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer ... PR ...","[{'ticker': 'AZN', 'relevance_score': '0.038717', 'ticker_sentiment_score': '0.062494', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ILMN', 'relevance_score': '0.337811', 'ticker_sentiment_score': '0.249481', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ABBV', 'relevance_score': '0.038717', 'ticker_sentiment_score': '0.062494', 'ticker_sentiment_label': 'Neutral'}]"
Johnson & Johnson sues Biden administration over Medicare drug price negotiations,20230718T170747,"Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA filed separate lawsuits against the provision last month.","[{'ticker': 'BMY', 'relevance_score': '0.207571', 'ticker_sentiment_score': '-0.261022', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'JNJ', 'relevance_score': '0.207571', 'ticker_sentiment_score': '-0.3699', 'ticker_sentiment_label': 'Bearish'}]"
"SARS-CoV-2 Is Not Done Yet - Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ",20230718T120740,"SARS-CoV-2 is not done yet - Although it is not grabbing as many headlines, the number of deaths arestill greater than even a pandemic influenza year at last count.","[{'ticker': 'APG', 'relevance_score': '0.05339', 'ticker_sentiment_score': '0.170729', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PFE', 'relevance_score': '0.106541', 'ticker_sentiment_score': '0.042105', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.106541', 'ticker_sentiment_score': '0.05881', 'ticker_sentiment_label': 'Neutral'}]"
"The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck - Illumina  ( NASDAQ:ILMN ) ",20230718T131500,"Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries SAN DIEGO, July 18, 2023 /PRNewswire/ -- Illumina Inc.","[{'ticker': 'GOOG', 'relevance_score': '0.037681', 'ticker_sentiment_score': '0.104057', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'META', 'relevance_score': '0.037681', 'ticker_sentiment_score': '0.104057', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.037681', 'ticker_sentiment_score': '0.058386', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.075279', 'ticker_sentiment_score': '0.076713', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ILMN', 'relevance_score': '0.329307', 'ticker_sentiment_score': '0.251401', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III",20230728T153200,"AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.","[{'ticker': 'AZN', 'relevance_score': '0.136422', 'ticker_sentiment_score': '0.045555', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KVUE', 'relevance_score': '0.163354', 'ticker_sentiment_score': '0.076801', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LLY', 'relevance_score': '0.054794', 'ticker_sentiment_score': '-0.022006', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.190096', 'ticker_sentiment_score': '0.052047', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.082111', 'ticker_sentiment_score': '-0.048804', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.054794', 'ticker_sentiment_score': '-0.070823', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.10933', 'ticker_sentiment_score': '0.070211', 'ticker_sentiment_label': 'Neutral'}]"
"The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets - PacWest Banc  ( NASDAQ:PACW ) , CVS Health  ( NYSE:CVS ) , JPMorgan Chase  ( NYSE:JPM ) , Merck & Co  ( NYSE:MRK ) , Amgen  ( NASDAQ:AMGN ) , Pfizer  ( NYSE:PFE ) , Peoples Trust Company  ( OTC:PPAL ) , Anheuser-Busch InBev  ( NYSE:BUD ) , Microsoft  ( NASDAQ:MSFT ) , Shopify  ( NYSE:SHOP ) , Starbucks  ( NASDAQ:SBUX ) , Qualcomm  ( NASDAQ:QCOM ) , Advanced Micro Devices  ( NASDAQ:AMD ) , Alibaba Gr Holding  ( NYSE:BABA ) , PayPal Holdings  ( NASDAQ:PYPL ) , Alphabet  ( NASDAQ:GOOG ) , Meta Platforms  ( NASDAQ:META ) , Bank of America  ( NYSE:BAC ) , ConocoPhillips  ( NYSE:COP ) , Banc of California  ( NYSE:BANC ) , HSBC Holdings  ( NYSE:HSBC ) , Intel  ( NASDAQ:INTC ) , Caterpillar  ( NYSE:CAT ) , Toyota Motor  ( NYSE:TM ) , Amazon.com  ( NASDAQ:AMZN ) ",20230728T200647,"The S&P 500 and other major indexes slid on Thursday but recovered on Friday to wrap up the week to the upside. The Dow Jones broke a 13-day winning streak Thursday, its best since 1987, and was up 0.65% on a weekly basis Friday. The Nasdaq Composite posted a weekly gain of 1.67%.","[{'ticker': 'BABA', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PACW', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.196637', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PYPL', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CVS', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'META', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.083342', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AAPL', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BAC', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.08371', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'COP', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JPM', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.08371', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BANC', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.196637', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AMGN', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MSFT', 'relevance_score': '0.227538', 'ticker_sentiment_score': '0.005545', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SHOP', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SBUX', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'QCOM', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'INTC', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.240528', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'CAT', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMD', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMZN', 'relevance_score': '0.114956', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program,20230807T110000,"HOUSTON, Aug. 07, 2023 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced ...","[{'ticker': 'MRKR', 'relevance_score': '0.121773', 'ticker_sentiment_score': '-0.035651', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSSMY', 'relevance_score': '0.024446', 'ticker_sentiment_score': '-0.096071', 'ticker_sentiment_label': 'Neutral'}]"
Merck Is Driving Ginkgo Bioworks Stock Higher Monday: What's Going On? - Ginkgo Bioworks Holdings  ( NYSE:DNA ) ,20230807T124420,Ginkgo Bioworks Holdings Inc DNA shares are trading higher Monday after the company announced a collaboration with Merck & Company Inc MRK focused on improving biologic manufacturing.,"[{'ticker': 'DNA', 'relevance_score': '0.850784', 'ticker_sentiment_score': '0.777041', 'ticker_sentiment_label': 'Bullish'}]"
MRK: 3 Pharma Stocks to Buy for Value Investors,20230807T143744,The pharmaceutical industry's expansion is being propelled by factors like improved healthcare accessibility and advancements in nanotechnology and generative AI for drug discovery.,"[{'ticker': 'ISEE', 'relevance_score': '0.064973', 'ticker_sentiment_score': '0.174339', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ALPMF', 'relevance_score': '0.032513', 'ticker_sentiment_score': '0.097174', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TARO', 'relevance_score': '0.224606', 'ticker_sentiment_score': '0.232593', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Ginkgo Bioworks Announces Collaboration with Merck to Improve Biologic Manufacturing - PR Newswire,20230807T110100,Ginkgo Bioworks Announces Collaboration with Merck to Improve Biologic Manufacturing PR ...,"[{'ticker': 'APG', 'relevance_score': '0.046907', 'ticker_sentiment_score': '0.181501', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DNA', 'relevance_score': '0.231332', 'ticker_sentiment_score': '0.288638', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring",20230807T210100,"Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed ... PR ...","[{'ticker': 'CARM', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ADCT', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'INFI', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FUSN', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRTX', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IOBT', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AVCTF', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GTHX', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'INCPF', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BGNE', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'URGN', 'relevance_score': '0.068112', 'ticker_sentiment_score': '-0.055541', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KNBWY', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ALPMF', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CMPX', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.023414', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MDNA', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'REGMF', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CRVS', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.059891', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NGM', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IKNA', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ELEV', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'INCY', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TARA', 'relevance_score': '0.068112', 'ticker_sentiment_score': '-0.032319', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ALXO', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.023414', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AURA', 'relevance_score': '0.045439', 'ticker_sentiment_score': '-0.031842', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IBRX', 'relevance_score': '0.068112', 'ticker_sentiment_score': '-0.055541', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KYKOF', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TRYIF', 'relevance_score': '0.022729', 'ticker_sentiment_score': '-0.039133', 'ticker_sentiment_label': 'Neutral'}]"
"Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling - CVS Health  ( NYSE:CVS ) , Delta Air Lines  ( NYSE:DAL ) ",20230807T115907,"The Nasdaq 100 closed lower on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.","[{'ticker': 'CVS', 'relevance_score': '0.431554', 'ticker_sentiment_score': '0.314525', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'JEF', 'relevance_score': '0.431554', 'ticker_sentiment_score': '0.24074', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DAL', 'relevance_score': '0.431554', 'ticker_sentiment_score': '0.266996', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'HCSG', 'relevance_score': '0.090816', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
"Federal Court Rules To Prohibit Access To Abortion Pill: Supreme Court To Weigh In - Johnson & Johnson  ( NYSE:JNJ ) , Merck & Co  ( NYSE:MRK ) , Pfizer  ( NYSE:PFE ) ",20230816T192307,"The 5th Circuit Court of Appeals ruled Wednesday to prohibit access to mifepristone, the drug known as the abortion pill, in a case filed against the Food and Drug Administration. The ruling will not take effect until the Supreme Court weighs in, which may not occur until next year, according to ...","[{'ticker': 'PFE', 'relevance_score': '0.295867', 'ticker_sentiment_score': '-0.08874', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.295867', 'ticker_sentiment_score': '-0.08874', 'ticker_sentiment_label': 'Neutral'}]"
MRK: Looking for a Value Investment? Check out These 3 Pharma Stocks,20230817T180621,MRK: Looking for a Value Investment? Check out These 3 Pharma ... ...,"[{'ticker': 'IVZ', 'relevance_score': '0.040691', 'ticker_sentiment_score': '0.244239', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'LPCN', 'relevance_score': '0.240489', 'ticker_sentiment_score': '0.189603', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PFE', 'relevance_score': '0.240489', 'ticker_sentiment_score': '0.267898', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Oncology Market's Huge Potential Puts These Stocks in Focus,20230828T123800,"The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.","[{'ticker': 'REGN', 'relevance_score': '0.107978', 'ticker_sentiment_score': '0.080642', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.161349', 'ticker_sentiment_score': '0.023487', 'ticker_sentiment_label': 'Neutral'}]"
"Merck  ( MRK ) , Eisai to End Keytruda-Lenvima Combo Cancer Study",20230828T144500,"With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.","[{'ticker': 'CORT', 'relevance_score': '0.151539', 'ticker_sentiment_score': '0.143092', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.201105', 'ticker_sentiment_score': '0.034259', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TCRT', 'relevance_score': '0.151539', 'ticker_sentiment_score': '0.010477', 'ticker_sentiment_label': 'Neutral'}]"
"AbbVie, Merck, Lilly Highlight Biden List For Price Cuts",20230829T132800,Pharmaceutical Stocks: Biden Administration Unveils 10 Drugs ... Investor's Business Daily ...,"[{'ticker': 'ABBV', 'relevance_score': '0.290607', 'ticker_sentiment_score': '0.311341', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AMGN', 'relevance_score': '0.423843', 'ticker_sentiment_score': '0.053971', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HZNP', 'relevance_score': '0.147818', 'ticker_sentiment_score': '-0.008377', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.423843', 'ticker_sentiment_score': '0.138684', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.147818', 'ticker_sentiment_score': '0.03379', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.290607', 'ticker_sentiment_score': '0.311341', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca",20230829T134500,"Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.","[{'ticker': 'REGN', 'relevance_score': '0.100518', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.150278', 'ticker_sentiment_score': '-0.032857', 'ticker_sentiment_label': 'Neutral'}]"
Better Pharma Growth Stock: Eli Lilly vs. Merck,20230829T141500,"This is a close contest, but there's a clear winner.","[{'ticker': 'LLY', 'relevance_score': '0.47672', 'ticker_sentiment_score': '0.411131', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'RXDX', 'relevance_score': '0.063594', 'ticker_sentiment_score': '0.061711', 'ticker_sentiment_label': 'Neutral'}]"
"Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations",20230829T192200,"Merck, Johnson & Johnson and Amgen are among the first drugmakers to have products chosen for a contentious initiative to rein in prescription-drug costs.","[{'ticker': 'AZN', 'relevance_score': '0.058188', 'ticker_sentiment_score': '0.011008', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSSMY', 'relevance_score': '0.058188', 'ticker_sentiment_score': '0.015135', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.058188', 'ticker_sentiment_score': '0.049067', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LLY', 'relevance_score': '0.058188', 'ticker_sentiment_score': '0.047971', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.058188', 'ticker_sentiment_score': '0.047971', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMGN', 'relevance_score': '0.058188', 'ticker_sentiment_score': '0.047971', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.116067', 'ticker_sentiment_score': '-0.026232', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference,20230830T120000,"HOUSTON, Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that ...","[{'ticker': 'MRKR', 'relevance_score': '0.190667', 'ticker_sentiment_score': '-0.05307', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Marker Therapeutics  ( NASDAQ:MRKR ) ,20230830T120038,"HOUSTON, Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. MRKR, a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F.","[{'ticker': 'MRKR', 'relevance_score': '0.28664', 'ticker_sentiment_score': '-0.070952', 'ticker_sentiment_label': 'Neutral'}]"
MRK: 3 Pharma Stocks to Buy Now for a Dose of Profit,20230906T160206,"The global pharma industry is predicted to grow in the long run, owing to an aging population's increasing medical needs, consistent discoveries in treating chronic illnesses, and the adoption of advanced technologies such as AI.","[{'ticker': 'GDRX', 'relevance_score': '0.19393', 'ticker_sentiment_score': '0.237609', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'TSOI', 'relevance_score': '0.03916', 'ticker_sentiment_score': '0.082069', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.117104', 'ticker_sentiment_score': '0.149387', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer,20230918T122900,"Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in the EU.","[{'ticker': 'BTTX', 'relevance_score': '0.318897', 'ticker_sentiment_score': '-0.007017', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CORT', 'relevance_score': '0.194763', 'ticker_sentiment_score': '0.112068', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DVAX', 'relevance_score': '0.194763', 'ticker_sentiment_score': '0.073902', 'ticker_sentiment_label': 'Neutral'}]"
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",20230918T210100,"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key ... PR ...","[{'ticker': 'GLTO', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IPHA', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BGNE', 'relevance_score': '0.069361', 'ticker_sentiment_score': '0.052186', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IMMP', 'relevance_score': '0.069361', 'ticker_sentiment_score': '0.052186', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'REPL', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FUSN', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BNTX', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SURF', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RKUNF', 'relevance_score': '0.046273', 'ticker_sentiment_score': '0.04824', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IOVA', 'relevance_score': '0.069361', 'ticker_sentiment_score': '0.052186', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AKESF', 'relevance_score': '0.046273', 'ticker_sentiment_score': '0.058004', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CALT', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'INCY', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EXEL', 'relevance_score': '0.046273', 'ticker_sentiment_score': '0.058004', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'IOBT', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KURA', 'relevance_score': '0.069361', 'ticker_sentiment_score': '0.052186', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NBTX', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'REGN', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VCNX', 'relevance_score': '0.023146', 'ticker_sentiment_score': '0.04357', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca",20230925T125500,"Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.","[{'ticker': 'AZN', 'relevance_score': '0.104683', 'ticker_sentiment_score': '0.091488', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.257805', 'ticker_sentiment_score': '0.044915', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.052455', 'ticker_sentiment_score': '-0.124581', 'ticker_sentiment_label': 'Neutral'}]"
"Merck  ( MRK ) , Eisai Combo Therapy Fail Two Lung Cancer Studies",20230925T160600,"Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.","[{'ticker': 'ANVS', 'relevance_score': '0.151222', 'ticker_sentiment_score': '0.038631', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.343619', 'ticker_sentiment_score': '-0.251354', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'SGEN', 'relevance_score': '0.249361', 'ticker_sentiment_score': '0.115196', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J",20231002T103100,"AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.","[{'ticker': 'LLY', 'relevance_score': '0.149192', 'ticker_sentiment_score': '0.022956', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.074926', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.037504', 'ticker_sentiment_score': '-0.12063', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.074926', 'ticker_sentiment_score': '0.113572', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.037504', 'ticker_sentiment_score': '-0.11573', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.074926', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
Allarity Therapeutics to Present at Biomarkers Europe 2023 - Allarity Therapeutics  ( NASDAQ:ALLR ) ,20231002T110000,"Allarity will present on development of several drug-specific DRP® companion diagnostics, and participate in a panel discussion with speakers from Merck and Roche","[{'ticker': 'ALLR', 'relevance_score': '0.275867', 'ticker_sentiment_score': '0.002138', 'ticker_sentiment_label': 'Neutral'}]"
FDA Accepts Merck's  ( MRK )  Filing for Sotatercept in PAH Disease,20231002T153400,The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.,"[{'ticker': 'UTHR', 'relevance_score': '0.448842', 'ticker_sentiment_score': '0.297158', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'BMY', 'relevance_score': '0.234307', 'ticker_sentiment_score': '0.094482', 'ticker_sentiment_label': 'Neutral'}]"
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study - Merck & Co  ( NYSE:MRK ) ,20231005T133557,Merck & Co Inc MRK announced that the Phase 3 AMBASSADOR ( A031501 ) trial ( KEYNOTE-123 ) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.,"[{'ticker': 'ALPMF', 'relevance_score': '0.447528', 'ticker_sentiment_score': '-0.3311', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'SGEN', 'relevance_score': '0.447528', 'ticker_sentiment_score': '-0.3311', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Merck's  ( MRK )  Meets Goal in Muscle-Invasive Bladder Cancer Study,20231006T160300,Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.,"[{'ticker': 'ANVS', 'relevance_score': '0.163539', 'ticker_sentiment_score': '0.037885', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SGEN', 'relevance_score': '0.21686', 'ticker_sentiment_score': '0.171218', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'VAXX', 'relevance_score': '0.21686', 'ticker_sentiment_score': '0.109159', 'ticker_sentiment_label': 'Neutral'}]"
"Top Stories Thursday, Oct 5: Disney Slashes Ticket Prices For Children, US Government Ceases Free Distribution Of Merck COVID Pill, UK Deep Dives Into Amazon And Microsoft's Cloud Power - Buckle  ( NYSE:BKE ) , Amazon.com  ( NASDAQ:AMZN ) ",20231005T140104,"The Walt Disney Company DIS has unveiled a new series of discounts for children visiting its iconic Disneyland and Disney World parks. This strategic move comes amidst a noticeable decline in attendance and hotel occupancy, a trend exacerbated by the inflationary pressures that have made ...","[{'ticker': 'MSFT', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.065845', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VFS', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.195941', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'T', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.01708', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.259537', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'CAG', 'relevance_score': '0.068502', 'ticker_sentiment_score': '-0.121431', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'STZ', 'relevance_score': '0.068502', 'ticker_sentiment_score': '-0.015264', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DOV', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BKE', 'relevance_score': '0.068502', 'ticker_sentiment_score': '-0.167724', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'CLX', 'relevance_score': '0.102595', 'ticker_sentiment_score': '-0.073141', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DELL', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.285825', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DIS', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'WMT', 'relevance_score': '0.068502', 'ticker_sentiment_score': '0.062025', 'ticker_sentiment_label': 'Neutral'}]"
CHMP Endorses Merck's  ( MRK )  Keytruda Expansion in Gastric Cancer,20231016T144700,"If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.","[{'ticker': 'ALLO', 'relevance_score': '0.321673', 'ticker_sentiment_score': '0.125573', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ANVS', 'relevance_score': '0.164282', 'ticker_sentiment_score': '0.038', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CORT', 'relevance_score': '0.321673', 'ticker_sentiment_score': '0.212895', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck's  ( MRK )  Keytruda Gets FDA Nod in Sixth NSCLC Indication,20231017T151100,FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.,"[{'ticker': 'ALLO', 'relevance_score': '0.170878', 'ticker_sentiment_score': '0.050482', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DCPH', 'relevance_score': '0.170878', 'ticker_sentiment_score': '-0.010022', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JAZZ', 'relevance_score': '0.226477', 'ticker_sentiment_score': '0.078964', 'ticker_sentiment_label': 'Neutral'}]"
"FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication - Merck & Co  ( NYSE:MRK ) ",20231017T112825,The FDA approved Merck & Co Inc's MRK Keytruda for resectable ( tumors ≥4 centimeters [cm] or node-positive ) non-small cell lung cancer ( NSCLC ) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after ...,"[{'ticker': 'AZN', 'relevance_score': '0.272788', 'ticker_sentiment_score': '-0.171685', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'MORN', 'relevance_score': '0.138464', 'ticker_sentiment_score': '-0.105216', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.272788', 'ticker_sentiment_score': '-0.171685', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
"Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC",20231025T141500,"Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.","[{'ticker': 'BMY', 'relevance_score': '0.201523', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BPMC', 'relevance_score': '0.344987', 'ticker_sentiment_score': '0.138282', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.101582', 'ticker_sentiment_score': '0.131226', 'ticker_sentiment_label': 'Neutral'}]"
"Merck third-quarter results beat estimates, boosted by cancer drug and vaccine growth",20231026T103200,Drugmaker raises full-year sales outlook but cuts earnings guidance as it digests recent deals ...,"[{'ticker': 'DSKYF', 'relevance_score': '0.18046', 'ticker_sentiment_score': '0.118423', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RXDX', 'relevance_score': '0.090816', 'ticker_sentiment_score': '0.028571', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.18046', 'ticker_sentiment_score': '0.118423', 'ticker_sentiment_label': 'Neutral'}]"
"Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth",20231026T103736,"Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook.","[{'ticker': 'SKXJF', 'relevance_score': '0.067727', 'ticker_sentiment_score': '0.236985', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DSKYF', 'relevance_score': '0.067727', 'ticker_sentiment_score': '0.236985', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MRNA', 'relevance_score': '0.067727', 'ticker_sentiment_score': '0.074172', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RXDX', 'relevance_score': '0.134968', 'ticker_sentiment_score': '-0.003702', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.067727', 'ticker_sentiment_score': '0.074172', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Q3 Earnings and Revenues Beat Estimates,20231026T115013,"Merck (MRK) delivered earnings and revenue surprises of 9.79% and 3.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?","[{'ticker': 'LLY', 'relevance_score': '0.139265', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
Merck's Heavyweight Cancer Drug Delivered Another Beat And Raise,20231026T132000,Merck Stock: Cancer Drug Keytruda Delivers Beat-And-Raise Third ... Investor's Business Daily ...,"[{'ticker': 'DSKYF', 'relevance_score': '0.101582', 'ticker_sentiment_score': '-0.074004', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ALKS', 'relevance_score': '0.101582', 'ticker_sentiment_score': '-0.048936', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.101582', 'ticker_sentiment_score': '-0.074004', 'ticker_sentiment_label': 'Neutral'}]"
Why Pharma Giant Merck's  ( MRK )  Shares Are Shooting Higher Today - Merck & Co  ( NYSE:MRK ) ,20231026T145531,"Merck & Company, Inc. MRK Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion, reflecting sustained growth in Oncology and Vaccines. Lagevrio Q3 sales jumped 51% Y/Y to $640 million, and GARDASIL / GARDASIL 9 sales grew 16% to $2.585 billion.","[{'ticker': 'SKXJF', 'relevance_score': '0.249106', 'ticker_sentiment_score': '0.065584', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.249106', 'ticker_sentiment_score': '0.065584', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.249106', 'ticker_sentiment_score': '0.259101', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ORINY', 'relevance_score': '0.126119', 'ticker_sentiment_score': '0.164012', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck  ( MRK )  Q3 Earnings Top Estimates, COVID Drug Boosts Sales",20231026T151300,Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.,"[{'ticker': 'SKXJF', 'relevance_score': '0.132806', 'ticker_sentiment_score': '0.034841', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.106423', 'ticker_sentiment_score': '0.165144', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DSKYF', 'relevance_score': '0.132806', 'ticker_sentiment_score': '0.034841', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.106423', 'ticker_sentiment_score': '-0.025234', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.079921', 'ticker_sentiment_score': '0.050166', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.02668', 'ticker_sentiment_score': '-0.001852', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Q3 2023 Earnings Call Transcript,20231026T180027,"MRK earnings call for the period ending September 30, 2023.","[{'ticker': 'BCS', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'C', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BAC', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PTAIF', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'WFC', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MS', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.044978', 'ticker_sentiment_score': '0.158713', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DSKYF', 'relevance_score': '0.044978', 'ticker_sentiment_score': '0.158713', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GS', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.0045', 'ticker_sentiment_score': '0.066163', 'ticker_sentiment_label': 'Neutral'}]"
"FDA Approves Lilly's Omvoh™  ( mirikizumab-mrkz ) , A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis",20231026T222400,"FDA Approves Lilly's Omvoh™ ( mirikizumab-mrkz ) , A First-in-Class Treatment for Adults with Moderately to Severely ... PR ...","[{'ticker': 'LLY', 'relevance_score': '0.351558', 'ticker_sentiment_score': '0.235349', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'META', 'relevance_score': '0.018187', 'ticker_sentiment_score': '0.153865', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NHPEF', 'relevance_score': '0.018187', 'ticker_sentiment_score': '-0.11338', 'ticker_sentiment_label': 'Neutral'}]"
"Why Nasdaq, S&P 500 Futures Are Sliding Today - Alphabet  ( NASDAQ:GOOGL ) , Mattel  ( NASDAQ:MAT ) , Ford Motor  ( NYSE:F ) , Merck & Co  ( NYSE:MRK ) ",20231026T113830,"A somber mood looms over Wall Street, stirred by lackluster earnings reports and relentless bond yield increases. Stock futures dipped early Thursday, with Meta Platforms, Inc.'s META impressive results failing to satisfy investors.","[{'ticker': 'MAT', 'relevance_score': '0.066877', 'ticker_sentiment_score': '-0.075039', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'META', 'relevance_score': '0.066877', 'ticker_sentiment_score': '-0.05393', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MO', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NOC', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'KO', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.137488', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BSX', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'F', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.156089', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IVZ', 'relevance_score': '0.033468', 'ticker_sentiment_score': '-0.030701', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LUV', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'STM', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HTZ', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MSFT', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.137488', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKYW', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MA', 'relevance_score': '0.033468', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ORLY', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CMA', 'relevance_score': '0.033468', 'ticker_sentiment_score': '0.052695', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'INTC', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'STX', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RCL', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CCZ', 'relevance_score': '0.033468', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'COF', 'relevance_score': '0.066877', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HAS', 'relevance_score': '0.066877', 'ticker_sentiment_score': '-0.024197', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMZN', 'relevance_score': '0.100168', 'ticker_sentiment_score': '0.053018', 'ticker_sentiment_label': 'Neutral'}]"
Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.,20231114T103000,"Investors appear to be taking the shifting picture in stride, partly because much of the responsibility appears to fall on Pfizer and Merck.","[{'ticker': 'PFE', 'relevance_score': '0.443626', 'ticker_sentiment_score': '-0.211056', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.,20231114T211900,"Investors appear to be taking the shifting picture in stride, partly because much of the responsibility appears to fall on Pfizer and Merck.","[{'ticker': 'PFE', 'relevance_score': '0.443626', 'ticker_sentiment_score': '-0.211056', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
2 Healthcare Stocks That Could Make You Richer,20231115T143700,Merck and Intuitive Surgical both still have bright futures ahead.,"[{'ticker': 'MDT', 'relevance_score': '0.05133', 'ticker_sentiment_score': '0.167044', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ISRG', 'relevance_score': '0.393462', 'ticker_sentiment_score': '0.325566', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"JNJ: Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV",20231115T163013,"JNJ: Analyzing Pharma Stock Giants: JNJ, MRK, and ...","[{'ticker': 'ABBV', 'relevance_score': '0.204072', 'ticker_sentiment_score': '0.142349', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NXGL', 'relevance_score': '0.029472', 'ticker_sentiment_score': '0.157367', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'RXDX', 'relevance_score': '0.029472', 'ticker_sentiment_score': '0.074984', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.204072', 'ticker_sentiment_score': '0.124423', 'ticker_sentiment_label': 'Neutral'}]"
"FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca - Bristol-Myers Squibb  ( NYSE:BMY ) ",20231116T114833,The FDA approved Bristol Myers Squibb And Co's BMY Augtyro ( repotrectinib ) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer ( NSCLC ) . The pharma giant added the drug via a $4.1 billion buyout of Turning Point Therapeutics ...,"[{'ticker': 'AZN', 'relevance_score': '0.27432', 'ticker_sentiment_score': '-0.586056', 'ticker_sentiment_label': 'Bearish'}, {'ticker': 'BMY', 'relevance_score': '0.401331', 'ticker_sentiment_score': '0.156825', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis - Merck  ( OTC:MKGAF ) , Merck  ( OTC:MKKGY ) ",20231206T134804,Merck KGaA MKGAF MKKGY says its two Phase 3 EVOLUTION trials ( evolutionRMS 1 and evolutionRMS 2 ) of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates ( ARR ) in people with relapsing multiple sclerosis ( RMS ) compared to Sanofi SA's SNY Aubagio ( ...,"[{'ticker': 'SNY', 'relevance_score': '0.327366', 'ticker_sentiment_score': '-0.128243', 'ticker_sentiment_label': 'Neutral'}]"
"Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%",20231214T134000,"Moderna's ( MRK ) Merck ( MRK ) -partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma patients, the companies said Thursday. The update fueled big gains for Moderna stock, which has been hamstrung recently on Covid news.","[{'ticker': 'MRNA', 'relevance_score': '0.601191', 'ticker_sentiment_score': '-0.466473', 'ticker_sentiment_label': 'Bearish'}, {'ticker': 'PFE', 'relevance_score': '0.148731', 'ticker_sentiment_score': '-0.151083', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
"Experimental cancer vaccine, combined with immunotherapy, continues to show benefits against melanoma, trial shows",20231214T135100,"An investigational mRNA vaccine used along with immunotherapy continues to show benefit for people with high-risk forms of the skin cancer melanoma, the drugmakers said Thursday. Experimental cancer vaccine combined with immunotherapy delayed return of melanoma, Moderna and Merck say","[{'ticker': 'MRNA', 'relevance_score': '0.349329', 'ticker_sentiment_score': '-0.403501', 'ticker_sentiment_label': 'Bearish'}, {'ticker': 'WBD', 'relevance_score': '0.179121', 'ticker_sentiment_score': '0.169676', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Moderna Stock Is Soaring Today - Here's Why - Merck & Co  ( NYSE:MRK ) , Moderna  ( NASDAQ:MRNA ) ",20231214T142222,"Moderna Inc MRNA and Merck & Co Inc MRK announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 ( V940 ) , an investigational individualized neoantigen therapy ( INT ) , in combination with Keytruda in patients with resected high-risk melanoma ( stage ...","[{'ticker': 'MRNA', 'relevance_score': '0.499789', 'ticker_sentiment_score': '0.111525', 'ticker_sentiment_label': 'Neutral'}]"
Moderna Stock Soars After Cancer Vaccine's Strong Test Results,20231214T163508,"Moderna's new mRNA vaccine reduces the chance of relapse or death of skin cancer by half when paired with Merck's immunotherapy drug Keytruda, new data shows, marking a step forward in the developing field of mRNA technology and sending Moderna's stock soaring Thursday morning.","[{'ticker': 'MRNA', 'relevance_score': '0.402941', 'ticker_sentiment_score': '-0.169424', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted' - Moderna  ( NASDAQ:MRNA ) ,20231214T210325,"Moderna, Inc. MRNA CEO Stéphane Bancel appeared on CNBC's ""Squawk Box"" Thursday to discuss the company's promising new cancer vaccine developed in partnership with Merck & Company, Inc. MRK.","[{'ticker': 'MRNA', 'relevance_score': '0.699089', 'ticker_sentiment_score': '-0.436498', 'ticker_sentiment_label': 'Bearish'}, {'ticker': 'PFE', 'relevance_score': '0.269776', 'ticker_sentiment_score': '-0.187431', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Moderna  ( MRNA )  Soars on Upbeat Data From Cancer Therapy Study,20231215T172700,Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.,"[{'ticker': 'MRNA', 'relevance_score': '0.514619', 'ticker_sentiment_score': '-0.019422', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GLPG', 'relevance_score': '0.324495', 'ticker_sentiment_score': '0.084811', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'OCUP', 'relevance_score': '0.110973', 'ticker_sentiment_score': '0.053649', 'ticker_sentiment_label': 'Neutral'}]"
FDA Expands Merck's  ( MRK )  Welireg Label in Renal Cell Carcinoma,20231215T173200,"Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.","[{'ticker': 'MRNA', 'relevance_score': '0.256719', 'ticker_sentiment_score': '-0.017999', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GLPG', 'relevance_score': '0.30569', 'ticker_sentiment_score': '0.080967', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'OCUP', 'relevance_score': '0.104228', 'ticker_sentiment_score': '0.052553', 'ticker_sentiment_label': 'Neutral'}]"
"Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility - Merck & Co  ( NYSE:MRK ) , Moderna  ( NASDAQ:MRNA ) ",20231216T195823,The U.S. Food and Drug Administration ( FDA ) identified several quality control issues at the primary manufacturing facility of Moderna Inc. MRNA during a September inspection.,"[{'ticker': 'MRNA', 'relevance_score': '0.626443', 'ticker_sentiment_score': '0.139688', 'ticker_sentiment_label': 'Neutral'}]"
"Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says",20231214T113001,"Those results build on midstage trial data Moderna and Merck released earlier this year, which examined the efficacy of the combination over a shorter period.","[{'ticker': 'MRNA', 'relevance_score': '0.158', 'ticker_sentiment_score': '-0.341563', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'JPM', 'relevance_score': '0.079392', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MS', 'relevance_score': '0.079392', 'ticker_sentiment_score': '-0.015767', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag,20231226T151000,"Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.","[{'ticker': 'ADMA', 'relevance_score': '0.342939', 'ticker_sentiment_score': '0.169826', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AGEN', 'relevance_score': '0.342939', 'ticker_sentiment_score': '0.022218', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.100941', 'ticker_sentiment_score': '0.143761', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.100941', 'ticker_sentiment_score': '0.143761', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PBYI', 'relevance_score': '0.200273', 'ticker_sentiment_score': '0.087662', 'ticker_sentiment_label': 'Neutral'}]"
C4 Therapeutics  ( CCCC )  Gains 310% in 3 Months: Here's Why,20240103T161000,C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.,"[{'ticker': 'DVAX', 'relevance_score': '0.388879', 'ticker_sentiment_score': '0.235093', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'CCCC', 'relevance_score': '0.328236', 'ticker_sentiment_score': '0.284956', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PBYI', 'relevance_score': '0.328236', 'ticker_sentiment_score': '0.252648', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck  ( MRK )  Keytruda Ok'd by FDA for Expanded Cervical Cancer Use,20240115T143000,FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.,"[{'ticker': 'FUSN', 'relevance_score': '0.316439', 'ticker_sentiment_score': '0.023179', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.064973', 'ticker_sentiment_score': '0.009134', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'REGN', 'relevance_score': '0.129516', 'ticker_sentiment_score': '0.052545', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.193207', 'ticker_sentiment_score': '0.045776', 'ticker_sentiment_label': 'Neutral'}]"
This 1 Bullish Move by Merck Could Drive Growth for Years to Come,20240123T134500,It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.,"[{'ticker': 'AMGN', 'relevance_score': '0.043658', 'ticker_sentiment_score': '-0.002968', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HARP', 'relevance_score': '0.087185', 'ticker_sentiment_score': '0.010581', 'ticker_sentiment_label': 'Neutral'}]"
Can Merck  ( MRK )  Keep the Beat Streak Alive in Q4 Earnings?,20240124T135400,"Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.","[{'ticker': 'AZN', 'relevance_score': '0.19661', 'ticker_sentiment_score': '-0.058353', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.244354', 'ticker_sentiment_score': '-0.001838', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release,20240125T150057,Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,"[{'ticker': 'PFE', 'relevance_score': '0.17618', 'ticker_sentiment_score': '-0.056009', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates",20240202T142100,"Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.","[{'ticker': 'AZN', 'relevance_score': '0.121241', 'ticker_sentiment_score': '0.03191', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.200688', 'ticker_sentiment_score': '0.114304', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.121241', 'ticker_sentiment_score': '0.03563', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.121241', 'ticker_sentiment_score': '0.071481', 'ticker_sentiment_label': 'Neutral'}]"
Elanco's stock heads for 18-month high as company sells aqua business to Merck for $1.3 billion in cash,20240205T114300,"The deal ""allows us to prioritize our investments in larger markets with greater earnings potential over the medium and long term, while creating balance sheet flexibility."" ...","[{'ticker': 'ELAN', 'relevance_score': '0.353898', 'ticker_sentiment_score': '0.192564', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'FOREX:VND', 'relevance_score': '0.12165', 'ticker_sentiment_score': '0.079117', 'ticker_sentiment_label': 'Neutral'}]"
"Why Is Elanco Animal Health Stock Trading Higher Today? - Elanco Animal Health  ( NYSE:ELAN ) , Merck & Co  ( NYSE:MRK ) ",20240205T154859,"Merck Animal Health, a division of Merck & Co Inc MRK, has agreed to acquire Elanco Animal Health Incorporated's aqua business ELAN for $1.3 billion in cash. The business consists of a portfolio of medicines and vaccines, nutrition, and supplements for aquatic species.","[{'ticker': 'ELAN', 'relevance_score': '0.337811', 'ticker_sentiment_score': '0.241862', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie, AstraZeneca, Merck & Co., Novartis, Pfizer and more",20240326T180000,"Global Urological Disorders Drugs Market Competitive Analysis, with Profiles of Leading Companies AbbVie ... PR ...","[{'ticker': 'AZN', 'relevance_score': '0.072655', 'ticker_sentiment_score': '0.028151', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.072655', 'ticker_sentiment_score': '0.028151', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.072655', 'ticker_sentiment_score': '0.028151', 'ticker_sentiment_label': 'Neutral'}]"
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment - Summit Therapeutics  ( NASDAQ:SMMT ) ,20240326T183648,"Stifel initiated coverage on Summit Therapeutics Inc SMMT, noting its main product ivonescimab, shows promising potential in two significant phase 3 trials for lung cancer treatment, with trial readouts expected in 2025.","[{'ticker': 'AKESF', 'relevance_score': '0.214937', 'ticker_sentiment_score': '0.207145', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SMMT', 'relevance_score': '0.504646', 'ticker_sentiment_score': '0.566764', 'ticker_sentiment_label': 'Bullish'}]"
Is This Merck's Next Big Billions-Of-Dollars Act After Keytruda?,20240326T211712,Merck Stock: Is The Cardiovascular Renaissance Here With Sotatercept Approval? Investor's Business Daily ...,"[{'ticker': 'MRNA', 'relevance_score': '0.045743', 'ticker_sentiment_score': '-0.237238', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
Merck  ( MRK )  Gets FDA Approval for New PAH Drug Winrevair,20240327T123900,Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.,"[{'ticker': 'ADMA', 'relevance_score': '0.38588', 'ticker_sentiment_score': '0.333986', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'UTHR', 'relevance_score': '0.199037', 'ticker_sentiment_score': '0.271387', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'JNJ', 'relevance_score': '0.13347', 'ticker_sentiment_score': '0.211276', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"After A 30% Fall In A Year, Is Pfizer Stock A Better Pick Over Merck?",20240402T110015,"Given its attractive valuation, we believe Pfizer stock ( NYSE: PFE ) is a better pick than its peer - Merck stock ( NYSE: MRK ) . MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth over the last year and a better financial position.","[{'ticker': 'PFE', 'relevance_score': '0.784319', 'ticker_sentiment_score': '0.342373', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck  ( MRK )  Begins Phase II/II Ovarian Cancer Study on ADC Drug,20240404T093600,Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.,"[{'ticker': 'ADMA', 'relevance_score': '0.419153', 'ticker_sentiment_score': '0.330193', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SKXJF', 'relevance_score': '0.419153', 'ticker_sentiment_score': '-0.050952', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.419153', 'ticker_sentiment_score': '-0.050952', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.217508', 'ticker_sentiment_score': '-0.086678', 'ticker_sentiment_label': 'Neutral'}]"
Why Is eFFECTOR Therapeutics Stock Plummeting On Thursday? - eFFECTOR Therapeutics  ( NASDAQ:EFTR ) ,20240404T143818,"Thursday, eFFECTOR Therapeutics Inc EFTR released topline results from the primary analysis of the Phase 2 KICKSTART trial, which tested tomivosertib or placebo, each combined with Merck & Co Inc's MRK Keytruda ( pembrolizumab ) , as a frontline treatment for patients with non-small cell lung ...","[{'ticker': 'EFTR', 'relevance_score': '0.276909', 'ticker_sentiment_score': '-0.067555', 'ticker_sentiment_label': 'Neutral'}]"
Pigment announces $145 million series D led by ICONIQ Growth,20240404T120000,"• The funding follows a record year for Pigment in which the company tripled its revenue, doubled its customer base globally, and on-boarded multiple major enterprise brands such as Unilever, Datadog, and Merck. • ICONIQ Growth who spearheaded Pigment's Series C last year also led the Series D ...","[{'ticker': 'BABA', 'relevance_score': '0.039548', 'ticker_sentiment_score': '0.153017', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GTLB', 'relevance_score': '0.039548', 'ticker_sentiment_score': '0.153017', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MQ', 'relevance_score': '0.039548', 'ticker_sentiment_score': '0.153017', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ADYYF', 'relevance_score': '0.039548', 'ticker_sentiment_score': '0.153017', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DDOG', 'relevance_score': '0.118257', 'ticker_sentiment_score': '0.151117', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'UL', 'relevance_score': '0.118257', 'ticker_sentiment_score': '0.135228', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABNB', 'relevance_score': '0.039548', 'ticker_sentiment_score': '0.153017', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DOCU', 'relevance_score': '0.039548', 'ticker_sentiment_score': '0.153017', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'UBER', 'relevance_score': '0.039548', 'ticker_sentiment_score': '0.153017', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
1 New Green Flag for Moderna and Merck Stock,20240412T124500,There's a new reason to believe that their joint projects are going well.,"[{'ticker': 'MRNA', 'relevance_score': '0.356317', 'ticker_sentiment_score': '0.164176', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Better Growth Play: Merck or The Vanguard Growth Index Fund?,20240415T130000,Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?,"[{'ticker': 'LLY', 'relevance_score': '0.062926', 'ticker_sentiment_score': '0.011109', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.062926', 'ticker_sentiment_score': '0.055011', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.062926', 'ticker_sentiment_score': '0.011109', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.062926', 'ticker_sentiment_score': '0.055011', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.062926', 'ticker_sentiment_score': '0.055011', 'ticker_sentiment_label': 'Neutral'}]"
How Should You Play Merck  ( MRK )  Stock Ahead of Q1 Earnings?,20240422T183900,"Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.","[{'ticker': 'FATE', 'relevance_score': '0.21193', 'ticker_sentiment_score': '-0.029867', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.128135', 'ticker_sentiment_score': '0.038634', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVAX', 'relevance_score': '0.170275', 'ticker_sentiment_score': '-0.157839', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?,20240424T131900,"Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.","[{'ticker': 'AZN', 'relevance_score': '0.039614', 'ticker_sentiment_score': '-0.008857', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.039614', 'ticker_sentiment_score': '-0.080241', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVS', 'relevance_score': '0.039614', 'ticker_sentiment_score': '0.342197', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ABBV', 'relevance_score': '0.234307', 'ticker_sentiment_score': '0.134722', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.196132', 'ticker_sentiment_score': '-0.010985', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.118452', 'ticker_sentiment_score': '0.061763', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.196132', 'ticker_sentiment_score': '0.04485', 'ticker_sentiment_label': 'Neutral'}]"
4 Large Drug Stocks to Hold on to Amid Industry Challenges,20240424T140900,"Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.","[{'ticker': 'LLY', 'relevance_score': '0.11349', 'ticker_sentiment_score': '0.144552', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GOOG', 'relevance_score': '0.022772', 'ticker_sentiment_score': '0.06641', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.135985', 'ticker_sentiment_score': '0.157325', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'CTLT', 'relevance_score': '0.022772', 'ticker_sentiment_score': '0.06641', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.135985', 'ticker_sentiment_score': '0.157325', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
MRK: 3 A-Rated Pharma Stocks to Buy for Long-Term Growth,20240502T130933,"Driven by increasing healthcare spending worldwide amid a rapidly aging population and rising prevalence of chronic illness, growing disposable incomes, and rapid technological advancements, the pharmaceutical industry is poised for steady growth.","[{'ticker': 'AZN', 'relevance_score': '0.192502', 'ticker_sentiment_score': '0.238085', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'TARO', 'relevance_score': '0.144999', 'ticker_sentiment_score': '0.091974', 'ticker_sentiment_label': 'Neutral'}]"
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration - Merck & Co  ( NYSE:MRK ) ,20240502T165354,"After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc MRK just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc MRNA in fighting melanoma.","[{'ticker': 'MRNA', 'relevance_score': '0.388018', 'ticker_sentiment_score': '0.038939', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.057767', 'ticker_sentiment_score': '-0.05802', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Ends Keytruda Combo Melanoma Study Due to Futility,20240514T132500,Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.,"[{'ticker': 'MRNA', 'relevance_score': '0.158868', 'ticker_sentiment_score': '-0.03604', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ANIP', 'relevance_score': '0.3115', 'ticker_sentiment_score': '0.309368', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'LGND', 'relevance_score': '0.3115', 'ticker_sentiment_score': '0.309368', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck Ends Keytruda Combo Melanoma Study Due to Futility - Ligand Pharmaceuticals  ( NASDAQ:LGND ) , ANI Pharmaceuticals  ( NASDAQ:ANIP ) ",20240514T183349,"Merck MRK announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor, Keytruda plus vibostolimab, its investigational anti-TIGIT antibody, as adjuvant treatment for patients with resected high-risk melanoma.","[{'ticker': 'MRNA', 'relevance_score': '0.157141', 'ticker_sentiment_score': '-0.037241', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ANIP', 'relevance_score': '0.308246', 'ticker_sentiment_score': '0.359344', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'LGND', 'relevance_score': '0.308246', 'ticker_sentiment_score': '0.359344', 'ticker_sentiment_label': 'Bullish'}]"
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday? - Merus  ( NASDAQ:MRUS ) ,20240524T174119,"Thursday, Merus N.V. MRUS announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology ( ASCO ) Annual Meeting website. Keytruda ( pembrolizumab ) is Merck & Co Inc's MRK top selling cancer drug.","[{'ticker': 'MRUS', 'relevance_score': '0.337811', 'ticker_sentiment_score': '0.115051', 'ticker_sentiment_label': 'Neutral'}]"
"Moderna, Merck say vaccine improved survival in patients with deadly skin cancer",20240603T130001,Nearly 75% of patients who took the cancer vaccine and Keytruda were alive without any signs or symptoms of their cancer returning at the 2½-year mark.,"[{'ticker': 'MRNA', 'relevance_score': '0.331024', 'ticker_sentiment_score': '-0.122383', 'ticker_sentiment_label': 'Neutral'}]"
"Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients Why Are Merck And Moderna Stocks Trading Higher On Monday? - Merck & Co  ( NYSE:MRK ) , Moderna  ( NASDAQ:MRNA ) ",20240603T142716,"Monday, Moderna Inc MRNA and Merck & Co Inc MRK announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study.","[{'ticker': 'MRNA', 'relevance_score': '0.493128', 'ticker_sentiment_score': '0.096771', 'ticker_sentiment_label': 'Neutral'}]"
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck,20240604T151257,What's a Cancer Vaccine? What To Know As Trials Show Promise Forbes ...,"[{'ticker': 'MRNA', 'relevance_score': '0.351273', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.008028', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BNTX', 'relevance_score': '0.051886', 'ticker_sentiment_score': '0.008028', 'ticker_sentiment_label': 'Neutral'}]"
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon - Pfizer  ( NYSE:PFE ) ,20240604T174509,"On Friday, Pfizer Inc PFE revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna MRNA and Merck & Co MRK also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine ...","[{'ticker': 'MRNA', 'relevance_score': '0.315397', 'ticker_sentiment_score': '0.087413', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.315397', 'ticker_sentiment_score': '-0.024105', 'ticker_sentiment_label': 'Neutral'}]"
"Company News for June 4, 2024",20240604T134500,"Companies In The Article Are:NVDA, MRK,MRNA, SPOT, SRCL and WM ...","[{'ticker': 'NVDA', 'relevance_score': '0.530253', 'ticker_sentiment_score': '0.231865', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MRNA', 'relevance_score': '0.530253', 'ticker_sentiment_score': '0.508663', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'SPOT', 'relevance_score': '0.530253', 'ticker_sentiment_score': '0.723506', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'SRCL', 'relevance_score': '0.530253', 'ticker_sentiment_score': '0.134699', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'WM', 'relevance_score': '0.530253', 'ticker_sentiment_score': '0.134699', 'ticker_sentiment_label': 'Neutral'}]"
Broader market outperforms; European mrkt opens higher,20240612T080600,"At 13:30 IST, the barometer index, the S&P BSE Sensex was jumped 406.63 points or 0.54% to 76,862.63. The Nifty 50 index gained 128.85 points or 0.55% to 23,393.70.","[{'ticker': 'TTAZF', 'relevance_score': '0.05339', 'ticker_sentiment_score': '-0.028076', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'OCPNF', 'relevance_score': '0.05339', 'ticker_sentiment_score': '0.128691', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MAHMF', 'relevance_score': '0.05339', 'ticker_sentiment_score': '-0.028076', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'UL', 'relevance_score': '0.05339', 'ticker_sentiment_score': '-0.028076', 'ticker_sentiment_label': 'Neutral'}]"
Summit  ( SMMT )  Stock Surges 57% in the Past Month: Here's Why,20240612T131400,Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.,"[{'ticker': 'AKESF', 'relevance_score': '0.162437', 'ticker_sentiment_score': '-0.011213', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ARQT', 'relevance_score': '0.215415', 'ticker_sentiment_score': '0.057417', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HRTX', 'relevance_score': '0.267413', 'ticker_sentiment_score': '0.120315', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.267413', 'ticker_sentiment_score': '0.202741', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs,20240621T134500,"FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.","[{'ticker': 'AZN', 'relevance_score': '0.11166', 'ticker_sentiment_score': '0.009107', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.11166', 'ticker_sentiment_score': '0.108087', 'ticker_sentiment_label': 'Neutral'}]"
"5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More - SPDR Series Trust SPDR S&P Biotech ETF  ( ARCA:XBI ) ",20240624T085147,"Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.","[{'ticker': 'SKXJF', 'relevance_score': '0.057907', 'ticker_sentiment_score': '-0.105976', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.115509', 'ticker_sentiment_score': '-0.118239', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'REGN', 'relevance_score': '0.115509', 'ticker_sentiment_score': '0.100268', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VRNA', 'relevance_score': '0.057907', 'ticker_sentiment_score': '0.03197', 'ticker_sentiment_label': 'Neutral'}]"
With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?,20240624T130030,We believe that the computing behemoth IBM ( NYSE: IBM ) is currently a better pick over the pharmaceuticals giant Merck ( NYSE: MRK ) . The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.,"[{'ticker': 'SSNLF', 'relevance_score': '0.031282', 'ticker_sentiment_score': '0.057947', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.031282', 'ticker_sentiment_score': '0.14694', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.031282', 'ticker_sentiment_score': '0.14694', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RXDX', 'relevance_score': '0.031282', 'ticker_sentiment_score': '0.017338', 'ticker_sentiment_label': 'Neutral'}]"
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors,20240624T110000,"Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing ...","[{'ticker': 'LGVN', 'relevance_score': '0.036869', 'ticker_sentiment_score': '0.058808', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MCRB', 'relevance_score': '0.036869', 'ticker_sentiment_score': '0.058808', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BCYC', 'relevance_score': '0.036869', 'ticker_sentiment_score': '0.058808', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'OMGA', 'relevance_score': '0.182782', 'ticker_sentiment_score': '0.245368', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck  ( MRK )  Gets CHMP Nod for PAH Drug Winrevair in Europe,20240701T093000,Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.,"[{'ticker': 'ABBV', 'relevance_score': '0.127456', 'ticker_sentiment_score': '0.150305', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GMAB', 'relevance_score': '0.063933', 'ticker_sentiment_score': '0.129126', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'UTHR', 'relevance_score': '0.190167', 'ticker_sentiment_score': '0.26268', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'JNJ', 'relevance_score': '0.127456', 'ticker_sentiment_score': '0.206629', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck  ( MRK )  Gets Exclusive Rights to Opevesostat From Partner,20240702T124300,Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.,"[{'ticker': 'BVS', 'relevance_score': '0.359881', 'ticker_sentiment_score': '0.307081', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ORINY', 'relevance_score': '0.123844', 'ticker_sentiment_score': '0.055513', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HRTX', 'relevance_score': '0.359881', 'ticker_sentiment_score': '0.20094', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Why Is Australia Based Immutep's Stock Soaring On Friday? - Immutep  ( NASDAQ:IMMP ) ,20240712T113958,"Friday, Immutep Limited IMMP released results from Cohort B of the TACTI-003 ( KEYNOTE-PNC-34 ) Phase 2b trial of eftilagimod alfa ( efti ) in combination with Merck & Co Inc MRK Keytruda ( pembrolizumab ) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma ...","[{'ticker': 'IMMP', 'relevance_score': '0.42503', 'ticker_sentiment_score': '-0.147353', 'ticker_sentiment_label': 'Neutral'}]"
Elanco  ( ELAN )  Stock Declines After Sale of Aqua Business,20240722T141800,Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.,"[{'ticker': 'ELAN', 'relevance_score': '0.12645', 'ticker_sentiment_score': '0.224961', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'HAE', 'relevance_score': '0.249744', 'ticker_sentiment_score': '0.229188', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'UHS', 'relevance_score': '0.30928', 'ticker_sentiment_score': '0.194137', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Should You Buy, Sell or Hold Merck  ( MRK )  Ahead of Q2 Earnings?",20240723T151700,"Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.","[{'ticker': 'ELAN', 'relevance_score': '0.069394', 'ticker_sentiment_score': '0.056407', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.069394', 'ticker_sentiment_score': '0.177799', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NVO', 'relevance_score': '0.03473', 'ticker_sentiment_score': '0.107472', 'ticker_sentiment_label': 'Neutral'}]"
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants - Merck & Co  ( NYSE:MRK ) ,20240723T190400,"On Tuesday, Merck & Co Inc MRK shared topline results from its Phase 2b/3 clinical trial ( MK-1654-004 ) of clesrovimab ( MK-1654 ) . Clesrovimab is the company's investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus ( RSV ) disease.","[{'ticker': 'AZN', 'relevance_score': '0.350564', 'ticker_sentiment_score': '-0.092298', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.238133', 'ticker_sentiment_score': '0.208593', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SNY', 'relevance_score': '0.238133', 'ticker_sentiment_score': '-0.068059', 'ticker_sentiment_label': 'Neutral'}]"
Top 3 Health Care Stocks That Are Set To Fly This Quarter - Merck & Co  ( NYSE:MRK ) ,20240801T131641,"The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.","[{'ticker': 'EW', 'relevance_score': '0.421485', 'ticker_sentiment_score': '-0.040047', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  to Buy Curon's Bispecific Antibody Drug for $1.3B,20240812T151800,Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.,"[{'ticker': 'ELAN', 'relevance_score': '0.124486', 'ticker_sentiment_score': '0.07693', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'RXDX', 'relevance_score': '0.062434', 'ticker_sentiment_score': '0.029048', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'TRDA', 'relevance_score': '0.304679', 'ticker_sentiment_score': '0.142563', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FULC', 'relevance_score': '0.304679', 'ticker_sentiment_score': '0.228135', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck  ( MRK )  Falls 10% in 3 Months: Should You Buy the Dip?,20240823T142300,Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.,"[{'ticker': 'LLY', 'relevance_score': '0.081552', 'ticker_sentiment_score': '0.110056', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.081552', 'ticker_sentiment_score': '-0.011422', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.081552', 'ticker_sentiment_score': '-0.011422', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ELAN', 'relevance_score': '0.081552', 'ticker_sentiment_score': '-0.019733', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.081552', 'ticker_sentiment_score': '-0.017938', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.040829', 'ticker_sentiment_score': '0.105277', 'ticker_sentiment_label': 'Neutral'}]"
"Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer - BeiGene  ( NASDAQ:BGNE ) , Merck & Co  ( NYSE:MRK ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",20240823T181048,"The FDA will hold an Oncologic Drugs Advisory Committee ( ODAC ) meeting on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and esophageal squamous cell carcinoma.","[{'ticker': 'BGNE', 'relevance_score': '0.255641', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.255641', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
"Top Analyst Reports for Costco, Merck & Linde",20240823T202300,"Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Merck & Co., Inc. (MRK) and Linde plc (LIN), as well as two micro-cap stocks Hamilton Beach Brands Holding Company (HBB) and Armanino Foods of Distinction, Inc. (AMNF).","[{'ticker': 'LIN', 'relevance_score': '0.054857', 'ticker_sentiment_score': '0.269434', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'HBB', 'relevance_score': '0.054857', 'ticker_sentiment_score': '0.225934', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'AMNF', 'relevance_score': '0.054857', 'ticker_sentiment_score': '0.360007', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'COST', 'relevance_score': '0.054857', 'ticker_sentiment_score': '0.492212', 'ticker_sentiment_label': 'Bullish'}]"
"Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs",20240830T153500,"LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.","[{'ticker': 'LLY', 'relevance_score': '0.21686', 'ticker_sentiment_score': '0.089869', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.031364', 'ticker_sentiment_score': '-0.122645', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.21686', 'ticker_sentiment_score': '0.082915', 'ticker_sentiment_label': 'Neutral'}]"
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data,20240830T160500,MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.,"[{'ticker': 'AZN', 'relevance_score': '0.238718', 'ticker_sentiment_score': '-0.09368', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BVS', 'relevance_score': '0.351392', 'ticker_sentiment_score': '0.185078', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'FULC', 'relevance_score': '0.295867', 'ticker_sentiment_score': '0.244034', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ",20240903T201753,"Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories. Rahway, New Jersey-based Merck just flashed a Death Cross, signaling potential trouble ahead. Foster City, California-based Gilead is basking in a Golden Cross, a sign of ...","[{'ticker': 'GILD', 'relevance_score': '0.371523', 'ticker_sentiment_score': '0.494514', 'ticker_sentiment_label': 'Bullish'}]"
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma,20240904T145100,MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.,"[{'ticker': 'LLY', 'relevance_score': '0.313817', 'ticker_sentiment_score': '0.152668', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PFE', 'relevance_score': '0.313817', 'ticker_sentiment_score': '0.148935', 'ticker_sentiment_label': 'Neutral'}]"
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results,20240904T145500,Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.,"[{'ticker': 'PCVX', 'relevance_score': '0.382925', 'ticker_sentiment_score': '0.204547', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GSK', 'relevance_score': '0.099476', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.29234', 'ticker_sentiment_score': '0.253275', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study,20240910T141100,"Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.","[{'ticker': 'LLY', 'relevance_score': '0.176717', 'ticker_sentiment_score': '0.112887', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AKESF', 'relevance_score': '0.059341', 'ticker_sentiment_score': '-0.059068', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.234119', 'ticker_sentiment_score': '-0.032497', 'ticker_sentiment_label': 'Neutral'}]"
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda,20240910T162000,Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.,"[{'ticker': 'AKESF', 'relevance_score': '0.08197', 'ticker_sentiment_score': '0.082577', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BVS', 'relevance_score': '0.242487', 'ticker_sentiment_score': '0.129167', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'FULC', 'relevance_score': '0.242487', 'ticker_sentiment_score': '0.194908', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SMMT', 'relevance_score': '0.356723', 'ticker_sentiment_score': '0.033509', 'ticker_sentiment_label': 'Neutral'}]"
Why Summit Therapeutics Rocketed Over 60% Today,20240909T180103,The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.,"[{'ticker': 'AKESF', 'relevance_score': '0.154951', 'ticker_sentiment_score': '-0.052662', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'C', 'relevance_score': '0.077845', 'ticker_sentiment_score': '0.129205', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.2306', 'ticker_sentiment_score': '0.249401', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma,20240919T142100,The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.,"[{'ticker': 'ILMN', 'relevance_score': '0.213674', 'ticker_sentiment_score': '0.168411', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'KRYS', 'relevance_score': '0.282234', 'ticker_sentiment_score': '0.23693', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'FULC', 'relevance_score': '0.282234', 'ticker_sentiment_score': '0.032061', 'ticker_sentiment_label': 'Neutral'}]"
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?,20240920T135500,Declining estimates and the recent price drop make investors skeptical about holding MRK stock.,"[{'ticker': 'SKXJF', 'relevance_score': '0.093836', 'ticker_sentiment_score': '-0.011806', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.093836', 'ticker_sentiment_score': '-0.011806', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ELAN', 'relevance_score': '0.093836', 'ticker_sentiment_score': '-0.020397', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.093836', 'ticker_sentiment_score': '-0.018625', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs",20240920T190000,"FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.","[{'ticker': 'AZN', 'relevance_score': '0.075754', 'ticker_sentiment_score': '-0.038812', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.03792', 'ticker_sentiment_score': '-0.107077', 'ticker_sentiment_label': 'Neutral'}]"
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers,20240923T135300,The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.,"[{'ticker': 'ANIP', 'relevance_score': '0.235823', 'ticker_sentiment_score': '0.253512', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'KRYS', 'relevance_score': '0.235823', 'ticker_sentiment_score': '0.205872', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'FULC', 'relevance_score': '0.235823', 'ticker_sentiment_score': '0.02777', 'ticker_sentiment_label': 'Neutral'}]"
Is Merck Stock a Buy?,20240929T102800,There is mounting pressure on the company's most prized franchise.,"[{'ticker': 'SMMT', 'relevance_score': '0.056943', 'ticker_sentiment_score': '0.088113', 'ticker_sentiment_label': 'Neutral'}]"
Could Summit Therapeutics Become the Next Merck?,20241004T114500,Recent developments are forcing comparisons between these two drugmakers.,"[{'ticker': 'AKESF', 'relevance_score': '0.159922', 'ticker_sentiment_score': '0.119556', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.68701', 'ticker_sentiment_score': '0.254098', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ",20241021T162839,"On Saturday, Gilead Sciences, Inc. GILD and Merck & Co. Inc. MRK revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational combination maintained a high ...","[{'ticker': 'GILD', 'relevance_score': '0.321673', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
"Gilead, MRK Report Data From Investigational Combination Study for HIV",20241021T175000,"GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.","[{'ticker': 'ALNY', 'relevance_score': '0.175859', 'ticker_sentiment_score': '0.076997', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.232996', 'ticker_sentiment_score': '0.152722', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?",20241021T190000,"We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.","[{'ticker': 'SKXJF', 'relevance_score': '0.095138', 'ticker_sentiment_score': '-0.047172', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EXEL', 'relevance_score': '0.095138', 'ticker_sentiment_score': '-0.066354', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.095138', 'ticker_sentiment_score': '-0.047172', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ELAN', 'relevance_score': '0.095138', 'ticker_sentiment_score': '-0.066354', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.095138', 'ticker_sentiment_score': '-0.018738', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Q3 Earnings and Revenues Top Estimates,20241031T114006,"Merck (MRK) delivered earnings and revenue surprises of 4.67% and 0.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?","[{'ticker': 'CLDX', 'relevance_score': '0.208764', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
"Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View",20241031T154200,"MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.","[{'ticker': 'ELEV', 'relevance_score': '0.090588', 'ticker_sentiment_score': '0.051518', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.030254', 'ticker_sentiment_score': '0.073391', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.030254', 'ticker_sentiment_score': '0.073391', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.090588', 'ticker_sentiment_score': '0.007359', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ESALF', 'relevance_score': '0.030254', 'ticker_sentiment_score': '-0.001886', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CSTL', 'relevance_score': '0.120582', 'ticker_sentiment_score': '0.072414', 'ticker_sentiment_label': 'Neutral'}]"
"Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Novo Nordisk  ( NYSE:NVO ) , Merck & Co  ( NYSE:MRK ) , Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) , Eli Lilly  ( NYSE:LLY ) ",20241108T193505,"The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.","[{'ticker': 'NVO', 'relevance_score': '0.148731', 'ticker_sentiment_score': '-0.288291', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'ALNY', 'relevance_score': '0.148731', 'ticker_sentiment_score': '0.292055', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GLDAF', 'relevance_score': '0.148731', 'ticker_sentiment_score': '0.112666', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LLY', 'relevance_score': '0.148731', 'ticker_sentiment_score': '-0.186951', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'ABBV', 'relevance_score': '0.148731', 'ticker_sentiment_score': '0.211306', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GILD', 'relevance_score': '0.221481', 'ticker_sentiment_score': '0.318081', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'BMY', 'relevance_score': '0.221481', 'ticker_sentiment_score': '0.230164', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SNY', 'relevance_score': '0.148731', 'ticker_sentiment_score': '0.116145', 'ticker_sentiment_label': 'Neutral'}]"
New Strong Sell Stocks for November 11th,20241111T062600,"AMRK, ANIK and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 11, 2024.","[{'ticker': 'ALG', 'relevance_score': '0.595343', 'ticker_sentiment_score': '-0.207512', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'ANIK', 'relevance_score': '0.595343', 'ticker_sentiment_score': '-0.220749', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'AMRK', 'relevance_score': '0.595343', 'ticker_sentiment_score': '0.171471', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma,20241118T153200,The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.,"[{'ticker': 'IMCR', 'relevance_score': '0.200688', 'ticker_sentiment_score': '0.030838', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ANIP', 'relevance_score': '0.265378', 'ticker_sentiment_score': '0.26841', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'CSTL', 'relevance_score': '0.265378', 'ticker_sentiment_score': '0.093608', 'ticker_sentiment_label': 'Neutral'}]"
Merck Stock Trades Near 52-Week Low: What's Next for Investors?,20241121T200000,"We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.","[{'ticker': 'SKXJF', 'relevance_score': '0.075279', 'ticker_sentiment_score': '-0.04806', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EXEL', 'relevance_score': '0.075279', 'ticker_sentiment_score': '-0.07054', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.075279', 'ticker_sentiment_score': '-0.04806', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.075279', 'ticker_sentiment_score': '-0.017682', 'ticker_sentiment_label': 'Neutral'}]"
"TOTAL WIRELESS, WALMART, CAPITAL ONE, MERCK, AND COORS RETURN, LOWE'S JOIN THE BIG3 AS SEASON 8 SPONSORS",20241120T160000,"BIG3 Welcomes New and Returning Sponsors Coming Off of Most Viewed Season Ever in 2024 LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Today, the BIG3 announced the return of several key sponsors ahead of Season 8, including Total Wireless, Walmart, Capital One, Merck, and Simply Spiked by Coors.","[{'ticker': 'PG', 'relevance_score': '0.061159', 'ticker_sentiment_score': '0.165215', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'WMT', 'relevance_score': '0.121959', 'ticker_sentiment_score': '0.080809', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success",20241129T200000,RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.,"[{'ticker': 'PSTX', 'relevance_score': '0.191549', 'ticker_sentiment_score': '0.118333', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.096477', 'ticker_sentiment_score': '-0.073587', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.144275', 'ticker_sentiment_score': '0.067967', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.048327', 'ticker_sentiment_score': '-0.128896', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis",20241202T100000,"Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.","[{'ticker': 'PSTX', 'relevance_score': '0.187827', 'ticker_sentiment_score': '0.097997', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.094576', 'ticker_sentiment_score': '-0.073236', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.141448', 'ticker_sentiment_score': '0.032951', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.047371', 'ticker_sentiment_score': '-0.12869', 'ticker_sentiment_label': 'Neutral'}]"
"Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader",20241204T120000,"CAMBRIDGE, Mass., Dec. 04, 2024 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. ( Nasdaq: BEAM ) , a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to ...","[{'ticker': 'BEAM', 'relevance_score': '0.162802', 'ticker_sentiment_score': '0.108753', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BIIB', 'relevance_score': '0.08183', 'ticker_sentiment_score': '0.060739', 'ticker_sentiment_label': 'Neutral'}]"
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC,20241204T174000,This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.,"[{'ticker': 'SKXJF', 'relevance_score': '0.113866', 'ticker_sentiment_score': '0.018258', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.170075', 'ticker_sentiment_score': '0.093815', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.113866', 'ticker_sentiment_score': '0.018258', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.225425', 'ticker_sentiment_score': '0.102255', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.279653', 'ticker_sentiment_score': '0.116234', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium,20241210T133000,"HOUSTON, Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that ...","[{'ticker': 'MRKR', 'relevance_score': '0.293214', 'ticker_sentiment_score': '0.185267', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - Marker Therapeutics  ( NASDAQ:MRKR ) ,20241210T133044,"HOUSTON, Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Marker Therapeutics, Inc.","[{'ticker': 'MRKR', 'relevance_score': '0.540042', 'ticker_sentiment_score': '0.273559', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer Study,20241210T150900,The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.,"[{'ticker': 'SPRO', 'relevance_score': '0.222838', 'ticker_sentiment_score': '0.035357', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.222838', 'ticker_sentiment_score': '-0.088683', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CSTL', 'relevance_score': '0.222838', 'ticker_sentiment_score': '0.115952', 'ticker_sentiment_label': 'Neutral'}]"
"AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients - AstraZeneca  ( NASDAQ:AZN ) , Merck & Co  ( NYSE:MRK ) ",20241211T191018,"AstraZeneca Plc AZN and Merck & Co Inc MRK, on Wednesday, announced long-term results from the OlympiA Phase 3 trial.","[{'ticker': 'AZN', 'relevance_score': '0.330286', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal,20241218T125907,"Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.","[{'ticker': 'AZN', 'relevance_score': '0.101582', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.101582', 'ticker_sentiment_score': '0.219926', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PFE', 'relevance_score': '0.101582', 'ticker_sentiment_score': '0.219926', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Merck to End Development of Two Cancer Candidates: Time to Sell?,20241218T144900,"We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.","[{'ticker': 'SKXJF', 'relevance_score': '0.073546', 'ticker_sentiment_score': '-0.048945', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'EXEL', 'relevance_score': '0.073546', 'ticker_sentiment_score': '-0.071373', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.073546', 'ticker_sentiment_score': '-0.048945', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.073546', 'ticker_sentiment_score': '-0.017609', 'ticker_sentiment_label': 'Neutral'}]"
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance,20241218T150000,"The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.","[{'ticker': 'AZN', 'relevance_score': '0.298567', 'ticker_sentiment_score': '0.281891', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SNY', 'relevance_score': '0.226301', 'ticker_sentiment_score': '0.228075', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"What's Going On With Viking Therapeutics Stock On Wednesday? - Viking Therapeutics  ( NASDAQ:VKTX ) , Merck & Co  ( NYSE:MRK ) ",20241218T181239,"On Wednesday, Merck & Co Inc MRK and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.","[{'ticker': 'VKTX', 'relevance_score': '0.301933', 'ticker_sentiment_score': '0.441213', 'ticker_sentiment_label': 'Bullish'}]"
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - Marker Therapeutics  ( NASDAQ:MRKR ) ,20241219T130550,"APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response ( CR ) MT-601 was observed to be well tolerated in all study participants with no observation of immune-effector cell associated ...","[{'ticker': 'MRKR', 'relevance_score': '0.181591', 'ticker_sentiment_score': '0.200957', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck & Co  ( MRK )  technical analysis - Merck & Co  ( NYSE:MRK ) , Hansoh Pharmaceutical Gr  ( OTC:HNSPF ) ",20241219T165436,"Shares of Merck ( MRK ) are trading sideways but are still in a downtrend. If they reach the $95.00 level, they may reverse and head higher. Shares of Merck & Co., Inc. MRK are trading flat on Thursday, but remain in a downtrend.","[{'ticker': 'HNSPF', 'relevance_score': '0.09439', 'ticker_sentiment_score': '0.038467', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PSNL', 'relevance_score': '0.277958', 'ticker_sentiment_score': '-0.154508', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
"Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals",20241220T122700,PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.,"[{'ticker': 'ABBV', 'relevance_score': '0.236205', 'ticker_sentiment_score': '0.121229', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.079788', 'ticker_sentiment_score': '-0.130229', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.311335', 'ticker_sentiment_score': '0.109548', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.236205', 'ticker_sentiment_score': '0.126318', 'ticker_sentiment_label': 'Neutral'}]"
"MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals",20241220T141800,"Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.","[{'ticker': 'SPRO', 'relevance_score': '0.225425', 'ticker_sentiment_score': '0.04798', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CSTL', 'relevance_score': '0.225425', 'ticker_sentiment_score': '0.048934', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.170075', 'ticker_sentiment_score': '0.135508', 'ticker_sentiment_label': 'Neutral'}]"
"Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?",20241221T112600,"The weight-loss biotech Viking Therapeutics ( NASDAQ: VKTX ) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck ( NYSE: MRK ) .Given that Viking doesn't yet have any products approved for sale, is this the start of the end, or just a rough ...","[{'ticker': 'VKTX', 'relevance_score': '0.207127', 'ticker_sentiment_score': '0.176869', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NVO', 'relevance_score': '0.05234', 'ticker_sentiment_score': '0.102858', 'ticker_sentiment_label': 'Neutral'}]"
Is Merck the Next Big Weight-Loss Stock?,20241222T114500,"Watch out, Eli Lilly and Novo Nordisk. Merck ( NYSE: MRK ) is hungrily looking to take a bite out of the weight-loss drugs market.Amidst an evolving field of competitors, the big pharma is committing a hearty chunk of cash in hopes of becoming a contender.","[{'ticker': 'LLY', 'relevance_score': '0.059785', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.119235', 'ticker_sentiment_score': '0.117125', 'ticker_sentiment_label': 'Neutral'}]"
"Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More - Eli Lilly  ( NYSE:LLY ) ",20241222T195134,"According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.","[{'ticker': 'ELAN', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.195574', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'VTRS', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.345107', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'LLY', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.262117', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ZTS', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.195574', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'IDXX', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.195574', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ABBV', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.396574', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'GILD', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.344367', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'REGN', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.217986', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'BMY', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.249624', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PRGO', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.345107', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Here's Why VKTX Stock Plummeted 18% on Wednesday,20241219T124100,The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.,"[{'ticker': 'LLY', 'relevance_score': '0.140076', 'ticker_sentiment_score': '0.167373', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GPCR', 'relevance_score': '0.046907', 'ticker_sentiment_score': '0.165505', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'VKTX', 'relevance_score': '0.40348', 'ticker_sentiment_score': '0.273705', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GS', 'relevance_score': '0.046907', 'ticker_sentiment_score': '0.134173', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.093653', 'ticker_sentiment_score': '0.142539', 'ticker_sentiment_label': 'Neutral'}]"
"Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug",20241219T132400,"Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.","[{'ticker': 'LLY', 'relevance_score': '0.244109', 'ticker_sentiment_score': '-0.044179', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VKTX', 'relevance_score': '0.184363', 'ticker_sentiment_score': '0.202224', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'GS', 'relevance_score': '0.061949', 'ticker_sentiment_score': '0.141057', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.061949', 'ticker_sentiment_score': '0.07801', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.244109', 'ticker_sentiment_score': '-0.064976', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.061949', 'ticker_sentiment_score': '0.07801', 'ticker_sentiment_label': 'Neutral'}]"
2 High-Yield Dividend Stocks to Buy Early in 2025,20241231T124500,"The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb ( NYSE: BMY ) and Merck & Co. ( NYSE: MRK ) stand out for their combination of above-average dividend yields and proven business models.","[{'ticker': 'BMY', 'relevance_score': '0.280938', 'ticker_sentiment_score': '0.578473', 'ticker_sentiment_label': 'Bullish'}]"
"Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside - Absci  ( NASDAQ:ABSI ) ",20250122T182246,"Needham initiates Absci coverage with a Buy rating and a $9 price target, citing robust proprietary technology. Absci's partnerships with Merck, AstraZeneca, and Almirall provide milestone payments and royalties with lower financial risks.","[{'ticker': 'AMD', 'relevance_score': '0.162255', 'ticker_sentiment_score': '0.210796', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ABSI', 'relevance_score': '0.780804', 'ticker_sentiment_score': '0.456766', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'AZN', 'relevance_score': '0.241284', 'ticker_sentiment_score': '-0.003845', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LBTSF', 'relevance_score': '0.162255', 'ticker_sentiment_score': '-0.002852', 'ticker_sentiment_label': 'Neutral'}]"
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond,20250127T134500,"Last year wasn't a good one for Merck ( NYSE: MRK ) , one of the largest pharmaceutical companies in the world. The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine Keytruda.","[{'ticker': 'SMMT', 'relevance_score': '0.054857', 'ticker_sentiment_score': '-0.009031', 'ticker_sentiment_label': 'Neutral'}]"
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer,20250127T154100,The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.,"[{'ticker': 'ESALF', 'relevance_score': '0.113597', 'ticker_sentiment_score': '-0.0493', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VYGR', 'relevance_score': '0.224903', 'ticker_sentiment_score': '0.031793', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CSTL', 'relevance_score': '0.224903', 'ticker_sentiment_score': '0.139612', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HRMY', 'relevance_score': '0.224903', 'ticker_sentiment_score': '0.184366', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?",20250128T142400,"When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.","[{'ticker': 'LLY', 'relevance_score': '0.070002', 'ticker_sentiment_score': '0.097823', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.035035', 'ticker_sentiment_score': '-0.127385', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.070002', 'ticker_sentiment_score': '0.097823', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.035035', 'ticker_sentiment_score': '-0.127385', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.173832', 'ticker_sentiment_score': '0.060254', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.035035', 'ticker_sentiment_score': '0.093678', 'ticker_sentiment_label': 'Neutral'}]"
Merck  ( MRK )  Earnings Expected to Grow: Should You Buy?,20250128T150048,Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,"[{'ticker': 'ABBV', 'relevance_score': '0.175539', 'ticker_sentiment_score': '0.021243', 'ticker_sentiment_label': 'Neutral'}]"
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag,20250128T171000,"The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma. A decision is due on May 26, 2025.","[{'ticker': 'BMRN', 'relevance_score': '0.184363', 'ticker_sentiment_score': '0.064146', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CSTL', 'relevance_score': '0.244109', 'ticker_sentiment_score': '0.148998', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'HRMY', 'relevance_score': '0.244109', 'ticker_sentiment_score': '0.196668', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Top 3 Health Care Stocks You'll Regret Missing This Month - Radiopharm Theranostics  ( NASDAQ:RADX ) , Merck & Co  ( NYSE:MRK ) ",20250206T120146,"The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.","[{'ticker': 'RADX', 'relevance_score': '0.401331', 'ticker_sentiment_score': '-0.133333', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SRDX', 'relevance_score': '0.401331', 'ticker_sentiment_score': '0.203556', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Better High-Yield Dividend Stock: Pfizer vs. Merck,20250210T092900,"Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck ( NYSE: MRK ) that offer a yield above 3%, and shares of Pfizer ( NYSE: PFE ) offer a yield above 6%.Which of these ...","[{'ticker': 'PFE', 'relevance_score': '0.414559', 'ticker_sentiment_score': '0.30855', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'BMY', 'relevance_score': '0.048327', 'ticker_sentiment_score': '0.120916', 'ticker_sentiment_label': 'Neutral'}]"
"WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week  ( Feb 10-Feb 14 ) : Are The Others In Your Portfolio? - GeneDx Hldgs  ( NASDAQ:WGS ) , CRISPR Therapeutics  ( NASDAQ:CRSP ) , WeRide  ( NASDAQ:WRD ) ",20250216T144519,"WeRide stock soared 97.62% following NVIDIA's disclosure of a significant share acquisition. SpringWorks Therapeutics surged 42.58% on news of potential acquisition talks with Merck KGaA. Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider ...","[{'ticker': 'SWTX', 'relevance_score': '0.360752', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
"Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More",20250221T134100,EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.,"[{'ticker': 'IONS', 'relevance_score': '0.28387', 'ticker_sentiment_score': '0.113292', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.144275', 'ticker_sentiment_score': '-0.102874', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.072435', 'ticker_sentiment_score': '-0.125911', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.28387', 'ticker_sentiment_score': '0.246277', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany",20250227T211500,"Significantly extends commercial reach of Growth Direct through expanded global sales channels. enables opportunities for collaboration on supply chain efficiencies, services, and joint product development. Significantly extends commercial reach of Growth Direct through expanded global sales ...","[{'ticker': 'RPID', 'relevance_score': '0.152258', 'ticker_sentiment_score': '0.308484', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?",20250228T134500,"We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.","[{'ticker': 'AKESF', 'relevance_score': '0.030878', 'ticker_sentiment_score': '0.156171', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SKXJF', 'relevance_score': '0.030878', 'ticker_sentiment_score': '0.04555', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.030878', 'ticker_sentiment_score': '0.04555', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.06171', 'ticker_sentiment_score': '0.057259', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.06171', 'ticker_sentiment_score': '0.162495', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm - Edison Intl  ( NYSE:EIX ) , Elastic  ( NYSE:ESTC ) ",20250226T020000,"NEW YORK, Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Edison International EIX, Elastic N.V. ESTC, Intellia Therapeutics, Inc.","[{'ticker': 'EIX', 'relevance_score': '0.19117', 'ticker_sentiment_score': '-0.155433', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'ESTC', 'relevance_score': '0.115416', 'ticker_sentiment_score': '0.025502', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NTLA', 'relevance_score': '0.265172', 'ticker_sentiment_score': '-0.007993', 'ticker_sentiment_label': 'Neutral'}]"
Merck Injects $1 Billion To Expand Vaccine Production In US - Merck & Co  ( NYSE:MRK ) ,20250311T152643,"Merck opened a $1 billion, 225,000-square-foot vaccine manufacturing facility in Durham, North Carolina, as part of its U.S. expansion. The company has invested over $12 billion in U.S. capital projects since 2018, with an additional $8 billion planned by 2028.","[{'ticker': 'LLY', 'relevance_score': '0.187463', 'ticker_sentiment_score': '0.079409', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.187463', 'ticker_sentiment_score': '-0.173808', 'ticker_sentiment_label': 'Somewhat-Bearish'}]"
"BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA®  ( pembrolizumab )  in Patients with Locally Advanced or Metastatic Solid Tumors",20250313T051700,"SHANGHAI, March 13, 2025 /PRNewswire/ -- BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical trial collaboration agreement with MSD ( Merck & Co., Inc., Rahway, NJ, USA ) , to evaluate the combination of BioCity's ...","[{'ticker': 'AZN', 'relevance_score': '0.072217', 'ticker_sentiment_score': '-0.005117', 'ticker_sentiment_label': 'Neutral'}]"
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock,20250319T141100,"We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.","[{'ticker': 'AKESF', 'relevance_score': '0.03473', 'ticker_sentiment_score': '0.158008', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SKXJF', 'relevance_score': '0.03473', 'ticker_sentiment_score': '0.046109', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.03473', 'ticker_sentiment_score': '0.046109', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.069394', 'ticker_sentiment_score': '0.008162', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.069394', 'ticker_sentiment_score': '0.163773', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Which Dow Jones Stock Is Cheaper, Amgen or Merck?",20250328T123000,"Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, biotechnology giant Amgen ( NASDAQ: AMGN ) has been the best-performing stock in 2025, returning an impressive 21% year to date.","[{'ticker': 'AMGN', 'relevance_score': '0.684999', 'ticker_sentiment_score': '0.425038', 'ticker_sentiment_label': 'Bullish'}]"
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda,20250328T152000,"The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.","[{'ticker': 'ANIP', 'relevance_score': '0.241924', 'ticker_sentiment_score': '0.148963', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'CTMX', 'relevance_score': '0.194632', 'ticker_sentiment_score': '0.080055', 'ticker_sentiment_label': 'Neutral'}]"
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference,20250401T120000,"HOUSTON, April 01, 2025 ( GLOBE NEWSWIRE ) -- MARKER THERAPEUTICS, INC. ( Nasdaq: MRKR ) , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief ...","[{'ticker': 'CCORF', 'relevance_score': '0.124164', 'ticker_sentiment_score': '0.357891', 'ticker_sentiment_label': 'Bullish'}, {'ticker': 'MRKR', 'relevance_score': '0.468029', 'ticker_sentiment_score': '0.311976', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - Marker Therapeutics  ( NASDAQ:MRKR ) ,20250401T120014,"HOUSTON, April 01, 2025 ( GLOBE NEWSWIRE ) -- MARKER THERAPEUTICS, INC. MRKR, a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive ...","[{'ticker': 'CCORF', 'relevance_score': '0.103778', 'ticker_sentiment_score': '0.335583', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'MRKR', 'relevance_score': '0.566143', 'ticker_sentiment_score': '0.286045', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Intellia, and Merck and Encourages Investors to Contact the Firm - Merck & Co  ( NYSE:MRK ) , FMC  ( NYSE:FMC ) ",20250402T010000,"NEW YORK, April 01, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FMC Corporation FMC, TransMedics Group, Inc. TMDX, Intellia Therapeutics, Inc.","[{'ticker': 'TMDX', 'relevance_score': '0.297661', 'ticker_sentiment_score': '-0.27435', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'NTLA', 'relevance_score': '0.261918', 'ticker_sentiment_score': '-0.009892', 'ticker_sentiment_label': 'Neutral'}]"
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up,20250401T174707,"AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.","[{'ticker': 'GS', 'relevance_score': '0.109289', 'ticker_sentiment_score': '0.044911', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.145364', 'ticker_sentiment_score': '0.027155', 'ticker_sentiment_label': 'Neutral'}]"
"PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",20250402T134300,"Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.","[{'ticker': 'APG', 'relevance_score': '0.078611', 'ticker_sentiment_score': '0.055105', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LLY', 'relevance_score': '0.306963', 'ticker_sentiment_score': '0.009111', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.23281', 'ticker_sentiment_score': '-0.114397', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.306963', 'ticker_sentiment_score': '0.009111', 'ticker_sentiment_label': 'Neutral'}]"
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes,20250407T123700,"Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.","[{'ticker': 'AZN', 'relevance_score': '0.062434', 'ticker_sentiment_score': '0.055638', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.062434', 'ticker_sentiment_score': '0.055638', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'APG', 'relevance_score': '0.062434', 'ticker_sentiment_score': '0.092812', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'LLY', 'relevance_score': '0.245959', 'ticker_sentiment_score': '0.094459', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.185781', 'ticker_sentiment_score': '0.089307', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AMGN', 'relevance_score': '0.185781', 'ticker_sentiment_score': '0.089307', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.185781', 'ticker_sentiment_score': '0.089307', 'ticker_sentiment_label': 'Neutral'}]"
Where Will Eli Lilly Be in 5 Years?,20250418T085100,"What a difference five years can make. Just look at Eli Lilly ( NYSE: LLY ) . In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer, and Merck boasting larger market caps.","[{'ticker': 'LLY', 'relevance_score': '0.702673', 'ticker_sentiment_score': '0.243905', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'NVO', 'relevance_score': '0.118354', 'ticker_sentiment_score': '0.116312', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.059341', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.059341', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?,20250422T113200,"When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.","[{'ticker': 'LLY', 'relevance_score': '0.063341', 'ticker_sentiment_score': '0.110329', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AKESF', 'relevance_score': '0.031696', 'ticker_sentiment_score': '0.15659', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'ABBV', 'relevance_score': '0.031696', 'ticker_sentiment_score': '0.105365', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.157483', 'ticker_sentiment_score': '0.059326', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.031696', 'ticker_sentiment_score': '0.105365', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.063341', 'ticker_sentiment_score': '0.162702', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?,20250422T130600,"Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.","[{'ticker': 'ABBV', 'relevance_score': '0.254878', 'ticker_sentiment_score': '0.097412', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.183616', 'ticker_sentiment_score': '0.081117', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.03704', 'ticker_sentiment_score': '-0.136139', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.110802', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'JNJ', 'relevance_score': '0.074001', 'ticker_sentiment_score': '0.041489', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.219477', 'ticker_sentiment_score': '-0.001688', 'ticker_sentiment_label': 'Neutral'}]"
"Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Merck & Co  ( NYSE:MRK ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",20250421T122510,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.","[{'ticker': 'C', 'relevance_score': '0.088147', 'ticker_sentiment_score': '-0.072172', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'WFC', 'relevance_score': '0.088147', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'BMY', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.119254', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'VTRS', 'relevance_score': '0.175221', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer - Gilead Sciences  ( NASDAQ:GILD ) ,20250421T184908,Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with more data expected. Markets are messy-but the right setups can still deliver triple-digit gains.,"[{'ticker': 'SSTK', 'relevance_score': '0.067158', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GILD', 'relevance_score': '0.263942', 'ticker_sentiment_score': '-0.106004', 'ticker_sentiment_label': 'Neutral'}]"
Akeso shares slump despite second China approval for lung cancer drug,20250428T071118,"Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck's Keytruda in phase three trial.","[{'ticker': 'AKESF', 'relevance_score': '0.247208', 'ticker_sentiment_score': '0.037529', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.062761', 'ticker_sentiment_score': '0.048578', 'ticker_sentiment_label': 'Neutral'}]"
"Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?",20250428T114800,"We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.","[{'ticker': 'AKESF', 'relevance_score': '0.028422', 'ticker_sentiment_score': '0.154823', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'SKXJF', 'relevance_score': '0.028422', 'ticker_sentiment_score': '0.045146', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.028422', 'ticker_sentiment_score': '0.045146', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'MRNA', 'relevance_score': '0.085122', 'ticker_sentiment_score': '0.007404', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SMMT', 'relevance_score': '0.056808', 'ticker_sentiment_score': '0.162087', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion - Merck & Co  ( NYSE:MRK ) , SpringWorks Therapeutics  ( NASDAQ:SWTX ) ",20250428T161758,"Merck acquires SpringWorks for $47/share, valuing it at $3.9B, with a 26% premium over its 20-day average price. SpringWorks' rare tumor treatments will boost Merck's revenue and help expand its U.S. healthcare presence. Don't face extreme market conditions unprepared.","[{'ticker': 'SWTX', 'relevance_score': '0.279653', 'ticker_sentiment_score': '0.212847', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business",20250428T061300,"- Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion ( €3.0 billion ...","[{'ticker': 'GOOG', 'relevance_score': '0.015006', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'META', 'relevance_score': '0.015006', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GS', 'relevance_score': '0.015006', 'ticker_sentiment_score': '0.077086', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SWTX', 'relevance_score': '0.059972', 'ticker_sentiment_score': '0.145255', 'ticker_sentiment_label': 'Neutral'}]"
"Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business - SpringWorks Therapeutics  ( NASDAQ:SWTX ) ",20250428T061333,"- Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion ( €3.0 billion ) - - Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's ...","[{'ticker': 'GOOG', 'relevance_score': '0.014775', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'META', 'relevance_score': '0.014775', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GS', 'relevance_score': '0.014775', 'ticker_sentiment_score': '0.076951', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SWTX', 'relevance_score': '0.059049', 'ticker_sentiment_score': '0.144181', 'ticker_sentiment_label': 'Neutral'}]"
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?,20250519T122900,Both PFE and MRK have strong product and pipeline portfolios in oncology.,"[{'ticker': 'LLY', 'relevance_score': '0.088255', 'ticker_sentiment_score': '-0.028316', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'ABBV', 'relevance_score': '0.029472', 'ticker_sentiment_score': '0.097717', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.029472', 'ticker_sentiment_score': '0.097717', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.088255', 'ticker_sentiment_score': '-0.028316', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.517302', 'ticker_sentiment_score': '0.121627', 'ticker_sentiment_label': 'Neutral'}]"
"MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug",20250520T142200,The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.,"[{'ticker': 'SKXJF', 'relevance_score': '0.267559', 'ticker_sentiment_score': '0.105251', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.267559', 'ticker_sentiment_score': '0.105251', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'AZN', 'relevance_score': '0.202366', 'ticker_sentiment_score': '-0.060308', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'PFE', 'relevance_score': '0.202366', 'ticker_sentiment_score': '0.116937', 'ticker_sentiment_label': 'Neutral'}]"
"The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie",20250519T135100,"Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.","[{'ticker': 'ABBV', 'relevance_score': '0.101725', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'GSK', 'relevance_score': '0.201803', 'ticker_sentiment_score': '0.102371', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.329992', 'ticker_sentiment_score': '0.028134', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SEPN', 'relevance_score': '0.067919', 'ticker_sentiment_score': '0.0', 'ticker_sentiment_label': 'Neutral'}]"
"Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Merck & Co  ( NYSE:MRK ) , Pfizer  ( NYSE:PFE ) ",20250522T121514,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.","[{'ticker': 'SKXJF', 'relevance_score': '0.089797', 'ticker_sentiment_score': '-0.236385', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'C', 'relevance_score': '0.089797', 'ticker_sentiment_score': '-0.065163', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'XRAY', 'relevance_score': '0.178459', 'ticker_sentiment_score': '0.266769', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'DSKYF', 'relevance_score': '0.089797', 'ticker_sentiment_score': '-0.236385', 'ticker_sentiment_label': 'Somewhat-Bearish'}, {'ticker': 'PFE', 'relevance_score': '0.178459', 'ticker_sentiment_score': '0.216068', 'ticker_sentiment_label': 'Somewhat-Bullish'}]"
"Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More",20250523T121600,NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.,"[{'ticker': 'VIGL', 'relevance_score': '0.088964', 'ticker_sentiment_score': '0.089846', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SKXJF', 'relevance_score': '0.1331', 'ticker_sentiment_score': '0.07041', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'DSKYF', 'relevance_score': '0.1331', 'ticker_sentiment_score': '0.07041', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'NVO', 'relevance_score': '0.532319', 'ticker_sentiment_score': '0.245757', 'ticker_sentiment_label': 'Somewhat-Bullish'}, {'ticker': 'PFE', 'relevance_score': '0.220008', 'ticker_sentiment_score': '0.025894', 'ticker_sentiment_label': 'Neutral'}, {'ticker': 'SNY', 'relevance_score': '0.220008', 'ticker_sentiment_score': '0.140717', 'ticker_sentiment_label': 'Neutral'}]"
